Schools

Hall-Younger, E., Tait, S. W.G. (2025) Mitochondria and cell death signalling. Current Opinion in Cell Biology, 94, (doi: 10.1016/j.ceb.2025.102510)

Farndale, L., Insall, R., Yuan, K. (2025) TriDeNT: Triple deep network training for privileged knowledge distillation in histopathology. Medical Image Analysis, 102, (doi: 10.1016/j.media.2025.103479)

Dehghani, P., Salehirozveh, M., Tajabadi, A., Yeung, C. C., Lam, M., Leung, H. Y., Roy, V. A.L. (2025) Next-gen point-of-care tool for ultra-sensitive detection of urinary spermine for prostate cancer diagnosis. ACS Sensors, (doi: 10.1021/acssensors.4c03250)

Ji, Y., Cutiongco, M. F.A., Jensen, B. S., Yuan, K. (2025) Generating realistic single-cell images from CellProfiler representations. Medical Image Analysis, (doi: 10.1016/j.media.2025.103574)

Dobbin, S. J. H., Mangion, K., Berry, C., Roditi, G., Basak, S., McClure, J. D., Brooksbank, K., Sonecki, P., Sourbron, S., Evans, J., White, J., Welsh, P., Butler, E., Venugopal, B., Touyz, R. M., Jones, R. J., Petrie, M. C., Lang, N. N. (2025) Vascular endothelial growth factor inhibitor-induced cardiotoxicity: prospective multimodality assessment incorporating cardiovascular magnetic resonance imaging. Heart, (doi: 10.1136/heartjnl-2024-325535)

Elyan, B. M.P., Tan, B., Lambourg, E., McAllister, D. A., Jones, R. J., Lang, N. N., Mark, P. B., Lees, J. S., Bell, S. (2025) Incidence of cancer in people with CKD not requiring kidney replacement therapy: a systematic review and meta-analysis. Clinical Kidney Journal, (doi: 10.1093/ckj/sfaf084)

Müller, M. et al. (2025) Human-correlated genetic models identify precision therapy for liver cancer. Nature, (doi: 10.1038/s41586-025-08585-z)

Coudray, N. et al. (2025) Self supervised artificial intelligence predicts poor outcome from primary cutaneous squamous cell carcinoma at diagnosis. npj Digital Medicine, 8, (doi: 10.1038/s41746-025-01496-3)

Lytras, S., Lamb, K. D., Ito, J., Grove, J., Yuan, K., Sato, K., Hughes, J., Robertson, D. L. (2025) Pathogen genomic surveillance and the AI revolution. Journal of Virology, 99, (doi: 10.1128/jvi.01601-24)

Hartley, A., Galbraith, L. C.A., Shaw, R., Tibbo, A., Veeratterapillay, R., Wilson, L., Heer, R., Blyth, K., Leung, H., Ahmad, I. (2025) Loss of ARID1A accelerates prostate tumourigenesis with a proliferative collagen-poor phenotype through co-operation with AP1 subunit cFos. British Journal of Cancer, (doi: 10.1038/s41416-025-02944-3)

Elbassioni, A. A. M. et al. (2025) Targeting Runx1 protects against heart failure with preserved ejection fraction. bioRxiv, (doi: 10.1101/2025.01.24.634831)

Iwata, T., Ammar, A., Maka, N., Jawny, J., Hay, J., Martinelli, S., Officer-Jones, L., Le Quesne, J., Lynch, G., McSorley, S., Edwards, J. (2025) Does Immune Suppression in the Pre-malignant Microenvironment of Colorectal Neoplastic Lesions Associate with Development of Metachronous Polyp and Cancer Risk?

Coudray, N., Occidental, M. A., Mantilla, J. G., Claudio Quiros, A., Yuan, K., Balko, J., Tsirigos, A., Jour, G. (2025) Quantitative and morphology-based deep convolutional neural network approaches for osteosarcoma survival prediction in the neoadjuvant and metastatic settings. Clinical Cancer Research, 31, pp. 365-375. (doi: 10.1158/1078-0432.ccr-24-2599)

Ibrahim, I., Kouli, O., Ilangovan, S., Sneddon, M., Nalagatla, S., Marshall, C., Dutto, L., Leung, H. Y., Ahmad, I. (2025) Impact of centralisation of radical prostatectomy driven by the introduction of robotic systems on positive surgical margin and biochemical recurrence in pT2 prostate cancer. Cancer Medicine, 14, (doi: 10.1002/cam4.70514)

Seyedshahi, F., Rakovic, K., Poulain, N., Claudio Quiros, A., Powley, I. R., Richards, C., Uraiby, H., Klebe, S., Nakas, A., Wilson, C., Sereno, M., Officer-Jones, L., Ficken, C., Teodosio, A., Ballantyne, F., Murphy, D., Yuan, K., Le Quesne, J. (2024) A histomorphological atlas of resected mesothelioma discovered by self-supervised learning from 3446 whole-slide images. bioRxiv, (doi: 10.1101/2024.11.18.624103)

Mariappan, P. et al. (2024) Achieving benchmarks for national quality indicators reduces recurrence and progression in non-muscle-invasive bladder cancer. European Urology Oncology, 7, pp. 1327-1337. (doi: 10.1016/j.euo.2024.01.012)

Williamson, A., Houston, P., Paterson, J., Chalmers, A. J., McLoone, P., Fullerton, N., Foo, S. Y., James, A., Nowicki, S. (2024) Dosimetric comparison of hippocampal sparing technologies in patients with low grade glioma. Neuro-Oncology Advances, 6, (doi: 10.1093/noajnl/vdae131)

Liu, D., Young, F., Lamb, K. D., Claudio Quiros, A., Pancheva, A., Miller, C., Macdonald, C., Robertson, D. L., Yuan, K. (2024) PLM-interact: extending protein language models to predict protein-protein interactions. bioRxiv, (doi: 10.1101/2024.11.05.622169)

Liu, D., Young, F., Lamb, K. D., Robertson, D. L., Yuan, K. (2024) Prediction of virus-host associations using protein language models and multiple instance learning. PLoS Computational Biology, 20, (doi: 10.1371/journal.pcbi.1012597)

Xavier, V., Martinelli, S., Corbyn, R., Pennie, R., Rakovic, K., Powley, I. R., Officer-Jones, L., Ruscica, V., Galloway, A., Carlin, L. M., Cowling, V. H., Le Quesne, J., Martinou, J.-C., MacVicar, T. (2024) Mitochondrial double-stranded RNA homeostasis depends on cell-cycle progression. Life Science Alliance, 7, (doi: 10.26508/lsa.202402764)

Hargrave, K. E., Worrell, J. C., Pirillo, C., Brennan, E., Masdefiol Garriga, A., Gray, J. I., Purnell, T., Roberts, E. W., MacLeod, M. K.L. (2024) Lung influenza virus specific memory CD4 T cell location and optimal cytokine production are dependent on interactions with lung antigen-presenting cells. Mucosal Immunology, 17, pp. 843-857. (doi: 10.1016/j.mucimm.2024.06.001)

Sahni, D. S., Morrison, J., Leung, H. Y. (2024) Grid-based cognitive diagnostic prostatic biopsies without transrectal ultrasound imaging. BJU International, 134, pp. 659-663. (doi: 10.1111/bju.16396)

Lamb, K. D., Hughes, J., Lytras, S., Young, F., Koci, O., Herzig, J., Lovell, S. C.,, Grove, J., Yuan, K., Robertson, D. L. (2024) From a single sequence to evolutionary trajectories: protein language models capture the evolutionary potential of SARS-CoV-2 protein sequences. bioRxiv, (doi: 10.1101/2024.07.05.602129)

Strathearn, L. S., Spender, L. C., Schoenherr, C., Mason, S., Edwards, R., Blyth, K., Inman, G. (2024) C1orf106 (INAVA) is a SMAD3-dependent TGF-β target gene that promotes clonogenicity and correlates with poor prognosis in breast cancer. Cells, 13, (doi: 10.3390/cells13181530)

Jackson, M. R., Richards, A. R., Oladipupo, A.-B. A., Chahal, S. K., Caragher, S., Chalmers, A. J., Gomez-Roman, N. (2024) ClonoScreen3D - a novel three-dimensional clonogenic screening platform for identification of radiosensitizers for glioblastoma. International Journal of Radiation Oncology, Biology, Physics, 120, pp. 162-177. (doi: 10.1016/j.ijrobp.2024.02.046)

Glover, H. L., Schreiner, A., Dewson, G., Tait, S. W.G. (2024) Mitochondria and cell death. Nature Cell Biology, 26, pp. 1434-1446. (doi: 10.1038/s41556-024-01429-4)

Elyan, B. M.P., Sullivan, M. K., Hedley, J., De La Mata, N., Webster, A. C., Venugopal, B., Jones, R. J., Lang, N. N., Mark, P. B., Lees, J. S. (2024) The impact of VEGF signalling pathway inhibitors and/or immune checkpoint inhibitors on kidney function over time: a single centre retrospective analysis. BJC Reports, 2, (doi: 10.1038/s44276-024-00081-7)

Lorimer, C., Mills, S., Chalmers, A., Coombes, I., Thompson, G., Glendenning, J., Radon, M., Jones, C., Williamson, A., Brock, J. (2024) Baseline total brain volume predicts changes in quality of life and overall survival after cranial radiotherapy in older patients with glioblastoma: Results from the prospective BRITER study. Neuro-Oncology Practice, 11, pp. 413-420. (doi: 10.1093/nop/npae019)

Boele, F., Rosenlund, L., Nordentoft, S., Melhuish, S., Nicklin, E., Rydén, I., Williamson, A., Donders-Kamphuis, M., Preusser, M., Le Rhun, E., Kiesel, B., Minniti, G., Furtner, J., Dirven, L., Taphoorn, M., Galldiks, N., Rudà, R., Chalmers, A., Short, S. C., Piil, K., the Nurse and Allied Health Professionals Committee, , the Disparity and Inclusion Committee of EANO, (2024) Inequalities in access to neuro-oncology supportive care and rehabilitation: a survey of healthcare professionals’ perspectives. Neuro-Oncology Practice, 11, pp. 484-493. (doi: 10.1093/nop/npae023)

Keith, N. et al. (2024) Emerging Ecologies of Health, Heritage, and Habitat: Looking into Living and Working in 2033. (doi: 10.17605/OSF.IO/BTNZ9)

Frankell, A. M. et al. (2024) Author Correction: The evolution of lung cancer and impact of subclonal selection in TRACERx. Nature, 631, (doi: 10.1038/s41586-024-07738-w)

Werner, J.-M., Petrescu, G. E.D., Boele, F., Preusser, M., Platten, M., Chalmers, A. J., Short, S. C., Piil, K. (2024) Chairing scientific sessions at international Neuro-Oncology meetings: an EANO guide for early-career professionals. Neuro-Oncology Practice, (doi: 10.1093/nop/npae060)

Quiros, A. C., Coudray, N., Yeaton, A., Yang, X., Liu, B., Le, H., Chiriboga, L., Karimkhan, A., Narula, N., Moore, D. A., Park, C. Y., Pass, H., Moreira, A. L., Le Quesne, J., Tsirigos, A., Yuan, K. (2024) Mapping the landscape of histomorphological cancer phenotypes using self-supervised learning on unannotated pathology slides. Nature Communications, 15, (doi: 10.1038/s41467-024-48666-7)

Kumar, S., Basto, A. P., Ribeiro, F., Almeida, S. C.P., Campos, P., Peres, C., Pulvirenti, N., Al-Khalidi, S., Kilbey, A., Tosello, J., Piaggio, E., Russo, M., Gama-Carvalho, M., Coffelt, S. B., Roberts, E. W., Geginat, J., Florindo, H. F., Graca, L. (2024) Specialized Tfh cell subsets driving type-1 and type-21 humoral responses in lymphoid tissue. Cell Discovery, 10, (doi: 10.1038/s41421-024-00681-0)

Wiesheu, R. et al. (2024) IL-27 maintains cytotoxic Ly6C+ T cells that arise from immature precursors. EMBO Journal, (doi: 10.1038/s44318-024-00133-1)

Rescigno, P. et al. (2024) Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial. European Journal of Cancer, 205, (doi: 10.1016/j.ejca.2024.114103)

Mardilovich, K., Naylor, G., Julian, L., Phinichkusolchit, N., Keeshan, K., Blyth, K., Olson, M. F. (2024) Caspase-resistant ROCK1 expression prolongs survival of Eµ-Myc B cell lymphoma mice. Disease Models and Mechanisms, 17, (doi: 10.1242/dmm.050631)

Ahmed Hassan Elshiekh, A., Tait, S. W.G. (2024) Tumour immunogenicity goes with the (mitochondrial electron) flow. Molecular Oncology, 18, pp. 1054-1057. (doi: 10.1002/1878-0261.13627)

Rankin, S., Elyan, B., Jones, R., Venugopal, B., Mark, P. B., Lees, J. S., Petrie, M. C., Lang, N. N. (2024) Cardiovascular eligibility criteria and adverse event reporting in combined immune checkpoint and VEGF inhibitors trials. JACC: CardioOncology, 6, pp. 267-279. (doi: 10.1016/j.jaccao.2023.12.010)

Bentley-Abbot, C., Heslop, R., Pirillo, C., Chandrasegaran, P., McConnell, G., Roberts, E., Hutchinson, E., MacLeod, A. (2024) An easy to use tool for the analysis of subcellular mRNA transcript colocalisation in smFISH data. Scientific Reports, 14, (doi: 10.1038/s41598-024-58641-3)

Derby, S., Jackson, M. R., Williams, K., Stobo, J., Kelly, C., Sweeting, L., Shad, S., Herbert, C., Short, S. C., Williamson, A., James, A., Nowicki, S., Bulbeck, H., Chalmers, A. (2024) Concurrent olaparib and radiotherapy in elderly patients with newly diagnosed glioblastoma: the phase I dose escalation PARADIGM trial. International Journal of Radiation Oncology, Biology, Physics, 118, pp. 1371-1378. (doi: 10.1016/j.ijrobp.2024.01.011)

Wakeham, K., Cooper, T., Rowbottom, C., Chalmers, A. J., Price, P., Quinlan, S., Spencer, K. (2024) Towards world-class radiotherapy in the UK: time for transformation. Lancet Oncology, 25, pp. 418-419. (doi: 10.1016/S1470-2045(24)00103-7)

Dehghani, P., Karthikeyan, V., Tajabadi, A., Assi, D. S., Catchpole, A., Wadsworth, J., Leung, H. Y., Roy, V. A.L. (2024) Rapid near-patient impedimetric sensing platform for prostate cancer diagnosis. ACS Omega, 9, pp. 14580-14591. (doi: 10.1021/acsomega.4c00843)

Derby, S., Jackson, M. R., Williams, K., Stobo, J., Kelly, C., Sweeting, L., Shad, S., Herbert, C., Short, S. C., Williamson, A., James, A., Nowicki, S., Bulbeck, H., Chalmers, A. J. (2024) Concurrent olaparib and radiation therapy in older patients with newly diagnosed glioblastoma: the phase 1 dose-escalation PARADIGM trial. International Journal of Radiation Oncology, Biology, Physics, 118, pp. 1371-1378. (doi: 10.1016/j.ijrobp.2024.01.011)

Tesson, M., Stevenson, K., Karim, S. A., Nixon, C., Chalmers, A. J., Sansom, O. J., O'Neill, E., Jones, K., Morton, J. P. (2024) Targeted irradiation in an autochthonous mouse model of pancreatic cancer. Disease Models and Mechanisms, 17, (doi: 10.1242/dmm.050463)

(2024) Special Issue – Cell and Tissue Polarity. Journal of Cell Science, 137,

Liu, B., Polack, M., Coudray, N., Quiros, A. C., Sakellaropoulos, T., Crobach, A. S.L.P., van Krieken, J. H. J.M., Yuan, K., Tollenaar, R. A.E.M., Mesker, W. E., Tsirigos, A. (2024) Self-supervised learning reveals clinically relevant histomorphological patterns for therapeutic strategies in colon cancer. bioRxiv, (doi: 10.1101/2024.02.26.582106)

Santi, A., Kay, E. J., Neilson, L. J., McGarry, L., Lilla, S., Mullin, M., Paul, N. R., Fercoq, F., Koulouras, G., Rodriguez Blanco, G., Athineos, D., Mason, S., Hughes, M., Thomson, G., Kieffer, Y., Nixon, C., Blyth, K., Mechta-Grigoriou, F., Carlin, L. M., Zanivan, S. (2024) Cancer-associated fibroblasts produce matrix-bound vesicles that influence endothelial cell function. Science Signaling, 17, (doi: 10.1126/scisignal.ade0580)

Critchlow, S., Bullement, A., Crabb, S., Jones, R., Christoforou, K., Amin, A., Xiao, Y., Kapetanakis, V., Benedict, Á., Chang, J., Kearney, M., Eccleston, A. (2024) Cost–effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in Scotland. Future Oncology, 20, pp. 459-470. (doi: 10.2217/fon-2023-0372)

Birtle, A. J., Jones, R., Chester, J., Lewis, R., Biscombe, K., Johnson, M., Blacker, A., Bryan, R., Catto, J. W.F., Choudhury, A., Das, P., Jagdev, S., Powles, T., Wagstaff, J., Cheung, K. C., Cafferty, F., Hall, E. (2024) Improved disease-free survival with adjuvant chemotherapy after nephroureterectomy for upper tract urothelial cancer: Final results of the POUT trial. Journal of Clinical Oncology, (doi: 10.1200/jco.23.01659)

Vringer, E., Heilig, R., Riley, J. S., Black, A., Cloix, C., Skalka, G., Montes-Gómez, A. E., Aguado, A., Lilla, S., Walczak, H., Gyrd-Hansen, M., Murphy, D. J., Huang, D. T., Zanivan, S., Tait, S. W.G. (2024) Mitochondrial outer membrane integrity regulates a ubiquitin-dependent and NF-κB-mediated inflammatory response. EMBO Journal, 43, pp. 904-930. (doi: 10.1038/s44318-024-00044-1)

Fizazi, K., Azad, A. A., Matsubara, N., Carles, J., Fay, A. P., De Giorgi, U., Joung, J. Y., Fong, P. C.C., Voog, E., Jones, R. J., Shore, N. D., Dunshee, C., Zschäbitz, S., Oldenburg, J., Ye, D., Lin, X., Healy, C. G., Di Santo, N., Laird, A. D., Zohren, F., Agarwal, N. (2024) Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nature Medicine, 30, (doi: 10.1038/s41591-024-02835-9)

Mahmood, M., Liu, E. M., Shergold, A. L., Tolla, E., Tait-Mulder, J., Huerta Uribe, A., Shokry, E., Young, A. L., Lilla, S., Kim, M., Park, T., Boscenco, S., Manchon, J. L., Rodríguez-Antona, C., Walters, R. C., Springett, R. J., Blaza, J. N., Mitchell, L., Blyth, K., Zanivan, S., Sumpton, D., Roberts, E. W., Reznik, E., Gammage, P. A. (2024) Mitochondrial DNA mutations drive aerobic glycolysis to enhance checkpoint blockade response in melanoma. Nature Cancer, (doi: 10.1038/s43018-023-00721-w)

Lamb, K. D., Luka, M. M., Saathoff, M., Orton, R. J., Phan, M. V.T., Cotten, M., Yuan, K., Robertson, D. L. (2024) Mutational signature dynamics indicate SARS-CoV-2's evolutionary capacity is driven by host antiviral molecules. PLoS Computational Biology, 20, (doi: 10.1371/journal.pcbi.1011795)

Welisch, G., Keith, N., Jones, R., Hanna, C. (2024) Creative approaches to reimagining patient and public involvement (PPI) in cancer research. (doi: 10.17605/OSF.IO/243XN)

Derby, S. et al. (2024) Inhibition of ATR opposes glioblastoma invasion through disruption of cytoskeletal networks and integrin internalisation via macropinocytosis. Neuro-Oncology, (doi: 10.1093/neuonc/noad210)

Bryant, D. M. (2023) We are the system. Journal of Cell Science, 136, (doi: 10.1242/jcs.261864)

Papalazarou, V., Newman, A. C., Huerta-Uribe, A., Legrave, N. M., Falcone, M., Zhang, T., McGarry, L., Athineos, D., Shanks, E., Blyth, K., Vousden, K. H., Maddocks, O. D. K. (2023) Phenotypic profiling of solute carriers characterises serine transport in cancer. Nature Metabolism, 5, pp. 2148-2168. (doi: 10.1038/s42255-023-00936-2)

Fizazi, K., Azad, A. A., Matsubara, N., Carles, J., Fay, A. P., De Giorgi, U., Joung, J. Y., Fong, P. C. C., Voog, E., Jones, R. J., Shore, N. D., Dunshee, C., Zschäbitz, S., Oldenburg, J., Ye, D., Lin, X., Healy, C. G., Di Santo, N., Laird, A. D., Zohren, F., Agarwal, N. (2023) First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: The phase 3 TALAPRO-2 trial. Nature Medicine, 30, pp. 257-264. (doi: 10.1038/s41591-023-02704-x)

Neilson, L. J., Cartwright, D., Risteli, M., Jokinen, E. M., McGarry, L., Sandvik, T., Nikolatou, K., Hodge, K., Atkinson, S., Vias, M., Kay, E. J., Brenton, J. D., Carlin, L. M., Bryant, D. M., Salo, T., Zanivan, S. (2023) Omentum-derived matrix enables the study of metastatic ovarian cancer and stromal cell functions in a physiologically relevant environment. Matrix Biology Plus, 19-20, (doi: 10.1016/j.mbplus.2023.100136)

Papalazarou, V., Newman, A. C., Huerta-Uribe, A., Legrave, N. M., Falcone, M., Zhang, T., McGarry, L., Athineos, D., Shanks, E., Blyth, K., Vousden, K. H., Maddocks, O. D. K. (2023) Phenotypic profiling of solute carriers characterizes serine transport in cancer. Nature Metabolism, 5, pp. 2148-2168. (doi: 10.1038/s42255-023-00936-2)

Taggart, R., Dutto, L., Leung, H. Y., Salji, M., Ahmad, I. (2023) A contemporary analysis of disease upstaging of Gleason 3+3 prostate cancer patients after Robot-Assisted Laparoscopic Prostatectomy (RALP) Cancer Medicine, 12, pp. 20830-20837. (doi: 10.1002/cam4.6651)

Conroy, S., Catto, J. W.F., Bex, A., Brown, J. E., Cartledge, J., Fielding, A., Jones, R. J., Khoo, V., Nicol, D., Stewart, G. D., Sullivan, M., Tran, M. G.B., Woodward, R., Cumberbatch, M. G. (2023) Diagnosis, treatment, and survival from kidney cancer: real‐world National Health Service England data between 2013 and 2019. BJU International, 132, pp. 541-553. (doi: 10.1111/bju.16128)

Martin, T. P., MacDonald, E. A., Bradley, A., Watson, H., Saxena, P., Rog-Zielinska, E. A., Raheem, A., Fisher, S., Elbassioni, A. A. M., Almuzaini, O., Booth, C., Campbell, M., Riddell, A., Herzyk, P., Blyth, K., Nixon, C., Zentilin, L., Berry, C., Braun, T., Giacca, M., McBride, M. W., Nicklin, S. R., Cameron, E. R., Loughrey, C. (2023) Ribonucleicacid interference or small molecule inhibition of Runx1 in the border zone prevents cardiac contractile dysfunction following myocardial infarction. Cardiovascular Research, 119, pp. 2663–2671-2663–2671. (doi: 10.1093/cvr/cvad107)

Victorelli, S. et al. (2023) Apoptotic stress causes mtDNA release during senescence and drives the SASP. Nature, 622, pp. 627-636. (doi: 10.1038/s41586-023-06621-4)

Grotehans, N., McGarry, L., Nolte, H., Xavier, V., Kroker, M., Narbona‐Pérez, Á. J., Deshwal, S., Giavalisco, P., Langer, T., MacVicar, T. (2023) Ribonucleotide synthesis by NME6 fuels mitochondrial gene expression. EMBO Journal, 42, (doi: 10.15252/embj.2022113256)

Dzien, P., Mackintosh, A., Malviya, G., Johnson, E., Soloviev, D., Brown, G., Huerta Uribe, A., Nixon, C., Lyons, S. K., Maddocks, O., Blyth, K., Lewis, D. (2023) Positron emission tomography imaging of the sodium iodide symporter senses real-time energy stress in vivo. Cancer and Metabolism, 11, (doi: 10.1186/s40170-023-00314-2)

Young, A. L., Lorimer, T., Al-Khalidi, S. K., Roberts, E. W. (2023) De novo priming: driver of immunotherapy responses or epiphenomenon? Essays In Biochemistry, 67, pp. 929-939. (doi: 10.1042/EBC20220244)

Nikolatou, K., Sandilands, E., Román-Fernández, A., Cumming, E. M., Freckmann, E., Lilla, S., Buetow, L., McGarry, L., Neilson, M., Shaw, R., Strachan, D., Miller, C., Huang, D. T., Mcneish, I. A., Norman, J. C., Zanivan, S., Bryant, D. M. (2023) PTEN deficiency exposes a requirement for an ARF GTPase module for integrin-dependent invasion in ovarian cancer. EMBO Journal, 42, (doi: 10.15252/embj.2023113987)

Kouli, O. O., McLoone, P., Morrison, D., Zaorsky, N. G., Chalmers, A. J. (2023) Risk of stroke-specific mortality after radiotherapy in patients with primary brain tumours. Clinical and Translational Radiation Oncology, 42, (doi: 10.1016/j.ctro.2023.100658)

Bailey, P., Ridgway, R. L., Cammareri, P., Treanor-Taylor, M., Bailey, U.-M., Schoenherr, C., Bone, M., Schreyer, D., Purdie, K., Thomson, J., Rickaby, W., Jackstadt, R., Campbell, A. D., Dimonitsas, E., Stratigos, A. J., Arron, S. T., Wang, J., Blyth, K., Proby, C. M., Harwood, C. A., Sansom, O. J., Leigh, I. M., Inman, G. J. (2023) Driver gene combinations dictate cutaneous squamous cell carcinoma disease continuum progression. Nature Communications, 14, (doi: 10.1038/s41467-023-40822-9)

Nikolatou, K., Bryant, D. M., Sandilands, E. (2023) The ARF GTPase regulatory network in collective invasion and metastasis. Biochemical Society Transactions, 51, pp. 1559-1569. (doi: 10.1042/BST20221355)

Suzuki, T. et al. (2023) β-catenin drives butyrophilin-like molecule loss and γδ T-cell exclusion in colon cancer. Cancer Immunology Research, 11, pp. 1137-1155. (doi: 10.1158/2326-6066.CIR-22-0644)

Ji, Y., Cutiongco, M. F.A., Jensen, B. S., Yuan, K. (2023) CP2Image: Generating High-Quality Single-Cell Images Using CellProfiler Representations.

Pirillo, C., Al Khalidi, S., Sims, A., Devlin, R., Zhao, H., Pinto, R., Jasim, S., Shearer, P. A., Shergold, A. L., Donnelly, H., Bravo-Blas, A., Loney, C., Perona-Wright, G., Hutchinson, E., Roberts, E. W. (2023) Cotransfer of antigen and contextual information harmonizes peripheral and lymph node conventional dendritic cell activation. Science Immunology, 8, (doi: 10.1126/sciimmunol.adg8249)

Elyan, B. M.P., Rankin, S., Jones, R., Lang, N. N., Mark, P. B., Lees, J. S. (2023) Kidney disease patient representation in trials of combination therapy with VEGF-signaling pathway inhibitors and immune checkpoint inhibitors: a systematic review. Kidney Medicine, 5, (doi: 10.1016/j.xkme.2023.100672)

Farahmand, P., Gyuraszova, K., Rooney, C., Raffo-Iraolagoitia, X. L., Jayasekera, G., Hedley, A., Johnson, E., Chernova, T., Malviya, G., Hall, H., Monteverde, T., Blyth, K., Duffin, R., Carlin, L. M., Lewis, D., le Quesne, J., MacFarlane, M., Murphy, D. J. (2023) Asbestos accelerates disease onset in a genetic model of malignant pleural mesothelioma. Frontiers in Toxicology, 5, (doi: 10.3389/ftox.2023.1200650)

Hatthakarnkul, P., Ammar, A., Pennel, K. A.F., Officer-Jones, L., Cusumano, S., Quinn, J. A., Matly, A. A. M., Alexander, P. G., Hay, J., Andersen, D., Lynch, G., Van Wyk, H. C., Maka, N., McMillan, D. C., Le Quesne, J., Thuwajit, C., Edwards, J. (2023) Protein expression of S100A2 reveals it association with patient prognosis and immune infiltration profile in colorectal cancer. Journal of Cancer, 14, pp. 1837-1847. (doi: 10.7150/jca.83910)

Tibbo, A. J., Hartley, A., Vasan, R., Shaw, R., Galbraith, L., Mui, E., Leung, H. Y., Ahmad, I. (2023) MBTPS2 acts as a regulator of lipogenesis and cholesterol synthesis through SREBP signalling in prostate cancer. British Journal of Cancer, 128, pp. 1991-1999. (doi: 10.1038/s41416-023-02237-7)

Catto, J. W.F., Mandrik, O., Quayle, L. A., Hussain, S. A., McGrath, J., Cresswell, J., Birtle, A. J., Jones, R. J., Mariappan, P., Makaroff, L. E., Knight, A., Mostafid, H., Chilcott, J., Sasieni, P., Cumberbatch, M. (2023) Diagnosis, treatment and survival from bladder, upper urinary tract, and urethral cancers: real-world findings from NHS England between 2013 and 2019. BJU International, 131, pp. 734-744. (doi: 10.1111/bju.15970)

Mar, N., Zakharia, Y., Falcon, A., Morales-Barrera, R., Mellado, B., Duran, I., Oh, D.-Y., Williamson, S. K., Gajate, P., Arkenau, H.-T., Jones, R. J., Teo, M. Y., Turan, T., McLaughlin, R. T., Peltier, H. M., Chong, E., Atluri, H., Dean, J. P., Castellano, D. (2023) Results from a phase 1b/2 study of ibrutinib combination therapy in advanced urothelial carcinoma. Cancers, 15, (doi: 10.3390/cancers15112978)

Zhang, H., AbdulJabbar, K., Moore, D. A., Akarca, A., Enfield, K., Jamal-Hanjani, M., Raza, S. E. A., Veeriah, S., Salgado, R., McGranahan, N., Le Quesne, J., Swanton, C., Marafioti, T., Yuan, Y. (2023) Spatial Positioning of Immune Hotspots Reflects the Interplay between B and T Cells in Lung Squamous Cell Carcinoma. Cancer Research, 83, pp. 1410-1425. (doi: 10.1158/0008-5472.CAN-22-2589)

Attard, G. et al. (2023) Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol. Lancet Oncology, 24, pp. 443-456. (doi: 10.1016/S1470-2045(23)00148-1)

May, S., Muller, M., Livingstone, C. R., Skalka, G. L., Walsh, P. J., Nixon, C., Hedley, A., Shaw, R., Clark, W., Voorde, J. V., Officer-Jones, L., Ballantyne, F., Powley, I. R., Drake, T. M., Kiourtis, C., Keith, A., Rocha, A. S., Tardito, S., Sumpton, D., Le Quesne, J., Bushell, M., Sansom, O. J., Bird, T. G. (2023) Absent expansion of AXIN2+ hepatocytes and altered physiology in Axin2CreERT2 mice challenges the role of pericentral hepatocytes in homeostatic liver regeneration. Journal of Hepatology, 78, pp. 1028-1036. (doi: 10.1016/j.jhep.2023.01.009)

Vitale, I. et al. (2023) Apoptotic cell death in disease—current understanding of the NCCD 2023. Cell Death and Differentiation, 30, pp. 1097-1154. (doi: 10.1038/s41418-023-01153-w)

Gillessen, S. et al. (2023) Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. European Journal of Cancer, 185, pp. 178-215. (doi: 10.1016/j.ejca.2023.02.018)

Lees, J. S., Elyan, B. M.P., Hermann, S. M., Lang, N. N., Jones, R. J., Mark, P. B. (2023) The ‘other’ big complication: how chronic kidney disease impacts on cancer risks and outcomes. Nephrology Dialysis Transplantation, 38, pp. 1071-1079. (doi: 10.1093/ndt/gfac011)

Ng, K. W. et al. (2023) Antibodies against endogenous retroviruses promote lung cancer immunotherapy. Nature, 616, pp. 563-573. (doi: 10.1038/s41586-023-05771-9)

Martínez-Ruiz, C. et al. (2023) Genomic–transcriptomic evolution in lung cancer and metastasis. Nature, 616, pp. 543-552. (doi: 10.1038/s41586-023-05706-4)

Frankell, A. M. et al. (2023) The evolution of lung cancer and impact of subclonal selection in TRACERx. Nature, 616, pp. 525-533. (doi: 10.1038/s41586-023-05783-5)

Al Bakir, M. et al. (2023) The evolution of non-small cell lung cancer metastases in TRACERx. Nature, 616, pp. 534-542. (doi: 10.1038/s41586-023-05729-x)

Abbosh, C. et al. (2023) Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA. Nature, 616, pp. 553-562. (doi: 10.1038/s41586-023-05776-4)

Hill, W. et al. (2023) Lung adenocarcinoma promotion by air pollutants. Nature, 616, pp. 159-167. (doi: 10.1038/s41586-023-05874-3)

Hartley, A., Ahmad, I. (2023) The role of PPARγ in prostate cancer development and progression. British Journal of Cancer, 128, pp. 940-945. (doi: 10.1038/s41416-022-02096-8)

Sandilands, E., Freckmann, E. C., Cumming, E. M., Román-Fernández, A., McGarry, L., Anand, J., Galbraith, L., Mason, S., Patel, R., Nixon, C., Cartwright, J., Leung, H. Y., Blyth, K., Bryant, D. M. (2023) The small GTPase ARF3 controls invasion modality and metastasis by regulating N-cadherin levels. Journal of Cell Biology, 222, (doi: 10.1083/jcb.202206115)

Al-Sawaf, O. et al. (2023) Body composition and lung cancer-associated cachexia in TRACERx. Nature Medicine, 29, pp. 846-858. (doi: 10.1038/s41591-023-02232-8)

Karasaki, T. et al. (2023) Evolutionary characterization of lung adenocarcinoma morphology in TRACERx. Nature Medicine, 29, pp. 833-845. (doi: 10.1038/s41591-023-02230-w)

Verhaegen, F., Butterworth, K. T., Chalmers, A. J., Coppes, R. P., de Ruysscher, D., Dobiasch, S., Fenwick, J. D., Granton, P. V., Heijmans, S. H.J., Hill, M. A., Koumenis, C., Lauber, K., Marples, B., Parodi, K., Persoon, L. C.G.G., Staut, N., Subiel, A., Vaes, R. D.W., van Hoof, S. J., Verginadis, I. L., Wilkens, J. J., Williams, K. J., Wilson, G. D., Dubois, L. J. (2023) Roadmap for precision preclinical x-ray radiation studies. Physics in Medicine and Biology, 68, (doi: 10.1088/1361-6560/acaf45)

Bennett, S. S., Leung, H. Y., Ahmad, I. (2023) A cohort analysis of patients receiving neoadjuvant androgen deprivation therapy prior to robot-assisted laparoscopic prostatectomy during the Covid-19 pandemic. Journal of Clinical Urology, 16, pp. 13-139. (doi: 10.1177/20514158211022216)

AlRasheedi, M., Han, S., Thygesen, H., Neilson, M., Hendry, F., Alkarn, A., Maclay, J. D., Leung, H. Y. (2023) A comparative evaluation of mediastinal nodal SUVmax and derived ratios from 18F-FDG PET/CT imaging to predict nodal metastases in non-small cell lung cancer. Diagnostics, 13, (doi: 10.3390/diagnostics13071209)

Villar, V. H., Allega, M. F., Deshmukh, R., Ackermann, T., Nakasone, M. A., Vande Voorde, J., Drake, T. M., Oetjen, J., Bloom, A., Nixon, C., Müller, M., May, S., Tan, E. H., Vereecke, L., Jans, M., Blancke, G., Murphy, D. J., Huang, D. T., Lewis, D. Y., Bird, T. G., Sansom, O. J., Blyth, K., Sumpton, D., Tardito, S. (2023) Hepatic glutamine synthetase controls N5-methylglutamine in homeostasis and cancer. Nature Chemical Biology, 19, pp. 292-300. (doi: 10.1038/s41589-022-01154-9)

Gillessen, S. et al. (2023) Management of patients with advanced prostate cancer. Part I: intermediate-/high-risk and locally advanced disease, biochemical relapse, and side effects of hormonal treatment: report of the advanced prostate cancer consensus conference 2022. European Urology, 83, pp. 267-293. (doi: 10.1016/j.eururo.2022.11.002)

Marchi, S., Guilbaud, E., Tait, S. W.G., Yamazaki, T., Galluzzi, L. (2023) Mitochondrial control of inflammation. Nature Reviews Immunology, 23, pp. 159-173. (doi: 10.1038/s41577-022-00760-x)

Schmidt, T., Dąbrowska, A., Waldron, J. A., Hodge, K., Koulouras, G., Gabrielsen, M., Munro, J., Tack, D. C., Harris, G., McGhee, E., Scott, D., Carlin, L. M., Huang, D., Le Quesne, J., Zanivan, S., Wilczynska, A., Bushell, M. (2023) eIF4A1-dependent mRNAs employ purine-rich 5’UTR sequences to activate localised eIF4A1-unwinding through eIF4A1-multimerisation to facilitate translation. Nucleic Acids Research, 51, pp. 1859-1879. (doi: 10.1093/nar/gkad030)

Heilig, R., Lee, J., Tait, S. W.G. (2023) Mitochondrial DNA in cell death and inflammation. Biochemical Society Transactions, 51, pp. 457-472. (doi: 10.1042/BST20221525)

Rushworth, L. K., Loveridge, C., Salji, M., MacLeod, M., Mui, E., Sumpton, D., Neilson, M., Hedley, A., Alexander, L., McCartney, E., Patel, R., Wallace, J., Delles, C., Jones, R., Leung, H. Y. (2023) Phase II proof of concept study of atorvastatin in castration resistant prostate cancer. BJU International, 131, pp. 236-243. (doi: 10.1111/bju.15851)

Khan, A. S., Campbell, K. J., Cameron, E. R., Blyth, K. (2023) The RUNX/CBFβ complex in breast cancer: a conundrum of context. Cells, 12, (doi: 10.3390/cells12040641)

Grocutt, L., Rutherford, A., Caldwell, D., Wilkinson, C., Chalmers, A.J., Dempsey, L., Kelly, C., O'Cathail, S.M. (2023) The impact of COVID-19 on radiotherapy services in Scotland, UK: a population-based study. Clinical Oncology, 35, pp. e227-e234. (doi: 10.1016/j.clon.2022.11.018)

Gravestock, P., Clark, E., Morton, M., Sharma, S., Fisher, H., Walker, J., Wood, R., Hancock, H., Waugh, N., Cooper, A., Maier, R., Marshall, J., Chandler, R., Bahl, A., Crabb, S., Jain, S., Pedley, I., Jones, R., Staffurth, J., Heer, R. (2023) Using the AR-V7 biomarker to determine treatment in metastatic castrate resistant prostate cancer, a feasibility randomised control trial, conclusions from the VARIANT trial. NIHR Open Research, 2, (doi: 10.3310/nihropenres.13284.2)

Koessinger, D., Novo, D., Koessinger, A., Campos, A., Peters, J., Dutton, L., Paschke, P., Zerbst, D., Moore, M., Mitchell, L., Neilson, M., Stevenson, K., Chalmers, A., Tait, S., Birch, J., Norman, J. (2023) Glioblastoma extracellular vesicles influence glial cell hyaluronic acid deposition to promote invasiveness. Neuro-Oncology Advances, 5, (doi: 10.1093/noajnl/vdad067)

Crabb, S. J., Hussain, S., Soulis, E., Hinsley, S., Dempsey, L., Trevethan, A., Song, Y., Barber, J., Frew, J., Gale, J., Faust, G., Brock, S., McGovern, U., Parikh, O., Enting, D., Sundar, S., Ratnayake, G., Lees, K., Birtle, A. J., Powles, T., Jones, R. J. (2023) A randomized, double-blind, biomarker-selected, phase ii clinical trial of maintenance poly adp-ribose polymerase inhibition with rucaparib following chemotherapy for metastatic urothelial carcinoma. Journal of Clinical Oncology, 41, pp. 54-64. (doi: 10.1200/JCO.22.00405)

O'Cathail, S.M., Chalmers, A.J. (2022) Integrating novel cancer therapies with radiation - illuminating the tunnel. Clinical Oncology, 35, pp. 38-41. (doi: 10.1016/j.clon.2022.10.010)

Román-Fernández, A. et al. (2022) Spatial regulation of the glycocalyx component podocalyxin is a switch for prometastatic function. Science Advances, 9, (doi: 10.1126/sciadv.abq1858)

Falcone, M., Huerta Uribe, A., Papalazarou, V., Newman, A. C., Athineos, D., Stevenson, K., Sauvé, C.-E. G., Gao, Y., Kim, J. K., Del Latto, M., Kierstead, M., Wu, C., Smith, J. J., Romesser, P. B., Chalmers, A. J., Blyth, K., Maddocks, O. D.K. (2022) Sensitisation of cancer cells to radiotherapy by serine and glycine starvation. British Journal of Cancer, 127, pp. 1773-1786. (doi: 10.1038/s41416-022-01965-6)

Sims, A., Tornaletti, L. B., Jasim, S., Pirillo, C., Devlin, R., Hirst, J. C., Loney, C., Wojtus, J., Sloan, E., Thorley, L., Boutell, C., Roberts, E., Hutchinson, E. (2022) Superinfection exclusion creates spatially distinct influenza virus populations. PLoS Biology, 21, (doi: 10.1371/journal.pbio.3001941)

Crabb, S. J., Griffiths, G., Dunkley, D., Downs, N., Ellis, M., Radford, M., Light, M., Northey, J., Whitehead, A., Wilding, S., Birtle, A. J., Khoo, V., Jones, R. J. (2022) Overall survival update for patients with metastatic castration-resistant prostate cancer treated with capivasertib and docetaxel in the phase 2 ProCAID clinical trial. European Urology, 82, pp. 512-515. (doi: 10.1016/j.eururo.2022.05.019)

Edwards, S. C., Hedley, A., Hoevenaar, W. H.M., Wiesheu, R., Glauner, T., Kilbey, A., Shaw, R., Boufea, K., Batada, N., Hatano, S., Yoshikai, Y., Blyth, K., Miller, C., Kirschner, K., Coffelt, S. B. (2022) PD-1 and TIM-3 differentially regulate subsets of mouse IL-17A–producing γδ T cells. Journal of Experimental Medicine, 220, (doi: 10.1084/jem.20211431)

Stewart, G. D. et al. (2022) A phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA) British Journal of Cancer, 127, pp. 1051-1060. (doi: 10.1038/s41416-022-01883-7)

Vringer, E., Tait, S. W.G. (2022) Mitochondria and cell death-associated inflammation. Cell Death and Differentiation, 30, pp. 304-312. (doi: 10.1038/s41418-022-01094-w)

Annese, V. F., Hu, C., Barrett, M. P., Jones, R., Cumming, D. R. S. (2022) A CMOS-based multi-omics detection platform for simultaneous quantification of proteolytically active prostate specific antigen and glutamate in urine. IEEE Sensors Journal, 22, pp. 18870-18877. (doi: 10.1109/JSEN.2022.3198282)

Leslie, J. et al. (2022) CXCR2 inhibition enables NASH-HCC immunotherapy. Gut, 71, pp. 2093-2106. (doi: 10.1136/gutjnl-2021-326259)

Koessinger, A. L. et al. (2022) Increased apoptotic sensitivity of glioblastoma enables therapeutic targeting by BH3-mimetics. Cell Death and Differentiation, 29, pp. 2089-2104. (doi: 10.1038/s41418-022-01001-3)

Ji, Y., Cutiongco, M. F.A., Jensen, B. S., Yuan, K. (2022) CP2Image: Generating High-Quality Single-Cell Images Using CellProfiler Representations.

Liu, X., Yang, X., Ouyang, L., Guo, G., Su, J., Xi, R., Yuan, K., Yuan, F. (2022) Protein Language Model Predicts Mutation Pathogenicity and Clinical Prognosis.

Freckmann, E. C., Sandilands, E., Cumming, E., Neilson, M., Roman-Fernandez, A., Nikolatou, K., Nacke, M., Lannagan, T. R.M., Hedley, A., Strachan, D., Salji, M., Morton, J. P., McGarry, L., Leung, H. Y., Sansom, O. J., Miller, C. J., Bryant, D. M. (2022) Traject3d allows label-free identification of distinct co-occurring phenotypes within 3D culture by live imaging. Nature Communications, 13, (doi: 10.1038/s41467-022-32958-x)

Kalkavan, H., Chen, M. J., Crawford, J. C., Quarato, G., Fitzgerald, P., Tait, S. W.G., Goding, C. R., Green, D. R. (2022) Sublethal cytochrome c release generates drug-tolerant persister cells. Cell, 185, pp. 3356-3374.e22. (doi: 10.1016/j.cell.2022.07.025)

Hanna, C.R., Lemmon, E., Hall, P.S., Ennis, H., Morris, E., McLoone, P., Boyd, K.A., Jones, R.J. (2022) Cancer trial impact: understanding implementation of the Short Course Oncology Treatment trial findings at a national level. Clinical Oncology, 34, pp. 554-560. (doi: 10.1016/j.clon.2022.03.012)

James, N. D. et al. (2022) Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5‐year follow‐up results from the STAMPEDE randomised trial (NCT00268476) International Journal of Cancer, 151, pp. 422-434. (doi: 10.1002/ijc.34018)

James, N. D. et al. (2022) Docetaxel for nonmetastatic prostate cancer: long-term survival outcomes in the STAMPEDE randomized controlled trial. JNCI Cancer Spectrum, 6, (doi: 10.1093/jncics/pkac043)

Patel, R., Ford, C. A., Rodgers, L., Rushworth, L. K., Fleming, J., Mui, E., Zhang, T., Watson, D., Lynch, V., Mackay, G., Sumpton, D., Sansom, O. J., Vande Voorde, J., Leung, H. Y. (2022) Cyclocreatine suppresses creatine metabolism and impairs prostate cancer progression. Cancer Research, 82, pp. 2565-2575. (doi: 10.1158/0008-5472.CAN-21-1301)

Zacharioudakis, E., Agianian, B., Kumar MV, V., Biris, N., Garner, T. P., Rabinovich-Nikitin, I., Ouchida, A. T., Margulets, V., Nordstrøm, L. U., Riley, J. S., Dolgalev, I., Chen, Y., Wittig, A. J. H., Pekson, R., Mathew, C., Wei, P., Tsirigos, A., Tait, S. W.G., Kirshenbaum, L. A., Kitsis, R. N., Gavathiotis, E. (2022) Modulating mitofusins to control mitochondrial function and signaling. Nature Communications, 13, (doi: 10.1038/s41467-022-31324-1)

Wilson, B. E., Armstrong, A. J., de Bono, J., Sternberg, C. N., Ryan, C. J., Scher, H. I., Smith, M. R., Rathkopf, D., Logothetis, C. J., Chi, K. N., Jones, R. J., Saad, F., De Porre, P., Tran, N., Hu, P., Gillessen, S., Carles, J., Fizazi, K., Joshua, A. M. (2022) Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302. European Journal of Cancer, 170, pp. 296-304. (doi: 10.1016/j.ejca.2022.03.042)

Sooriakumaran, P., Wilson, C., Rombach, I., Hassanali, N., Aning, J., D. Lamb, A., Cathcart, P., Eden, C., Ahmad, I., Rajan, P., Sridhar, A., Bryant, R. J., Elhage, O., Cook, J., Leung, H., Soomro, N., Kelly, J., Nathan, S., Donovan, J. L., Hamdy, F. C. (2022) Feasibility and safety of radical prostatectomy for oligo‐metastatic prostate cancer: the Testing Radical prostatectomy in men with prostate cancer and oligo‐Metastases to the bone (TRoMbone) trial. BJU International, 130, pp. 43-53. (doi: 10.1111/bju.15669)

Gillessen, S. et al. (2022) Management of patients with advanced prostate cancer: report from the advanced prostate cancer consensus conference 2021. European Urology, 82, pp. 115-141. (doi: 10.1016/j.eururo.2022.04.002)

Turco, F. et al. (2022) What experts think about prostate cancer management during the COVID-19 pandemic: report from the Advanced Prostate Cancer Consensus Conference 2021. European Urology, 82, pp. 6-11. (doi: 10.1016/j.eururo.2022.02.010)

Ahmed, A., Giampazolias, E., Patel, R., Leung, H., Tait, S. W.G. (2022) Caspase-independent cell death as a novel therapy for advanced prostate cancer.

Catto, J. W. F. et al. (2022) Effect of robot-assisted radical cystectomy with intracorporeal urinary diversion vs open radical cystectomy on 90-day morbidity and mortality among patients with bladder cancer. JAMA: Journal of the American Medical Association, 327, pp. 2092-2103. (doi: 10.1001/jama.2022.7393)

Parker, C. C. et al. (2022) Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial. PLoS Medicine, 19, (doi: 10.1371/journal.pmed.1003998)

Clarke, C. S., Hunter, R. M., Gabrio, A., Brawley, C. D., Ingleby, F. C., Dearnaley, D. P., Matheson, D., Attard, G., Rush, H. L., Jones, R. J., Cross, W., Parker, C., Russell, J. M., Millman, R., Gillessen, S., Malik, Z., Lester, J. F., Wylie, J., Clarke, N. W., Parmar, M. K. B., Sydes, M. R., James, N. D. (2022) Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data. PLoS ONE, 17, (doi: 10.1371/journal.pone.0269192)

Kay, E. J. et al. (2022) Cancer-associated fibroblasts require proline synthesis by PYCR1 for the deposition of pro-tumorigenic extracellular matrix. Nature Metabolism, 4, pp. 693-710. (doi: 10.1038/s42255-022-00582-0)

McAleavey, P. G., Walls, G. M., Chalmers, A. J. (2022) Radiotherapy-drug combinations in the treatment of glioblastoma: a brief review. CNS Oncology, 11, (doi: 10.2217/cns-2021-0015)

Bravo-Blas, A., Pirillo, C., Shergold, A., Andrusaite, A., Roberts, E. W. (2022) Think global but act local: Tuning the dendritic cell response in cancer. International Journal of Biochemistry and Cell Biology, 147, (doi: 10.1016/j.biocel.2022.106227)

Pirillo, C., Birch, F., Tissot, F., Anton, S. G., Haltalli, M., Tini, V., Kong, I., Piot, C., Partridge, B., Pospori, C., Keeshan, K., Santamaria, S., Hawkins, E., Falini, B., Marra, A., Duarte, D., Lee, C. F., Roberts, E., Celso, C. L. (2022) Metalloproteinase inhibition reduces AML growth, prevents stem cell loss and improves chemotherapy effectiveness. Blood Advances, 6, pp. 3126-3141. (doi: 10.1182/bloodadvances.2021004321)

Cao, K., Riley, J. S., Heilig, R., Montes-Gómez, A. E., Vringer, E., Berthenet, K., Cloix, C., Elmasry, Y., Spiller, D. G., Ichim, G., Campbell, K. J., Gilmore, A. P., Tait, S. W.G. (2022) Mitochondrial dynamics regulate genome stability via control of caspase-dependent DNA damage. Developmental Cell, 57, pp. 1211-1225.e6. (doi: 10.1016/j.devcel.2022.03.019)

Tait, S. W.G. (2022) Killing cells using light (activated) sabers. Journal of Cell Biology, 221, (doi: 10.1083/jcb.202205018)

Müller, M. et al. (2022) Human-correlated genetic HCC models identify combination therapy for precision medicine [Pre-print] Research Square, (doi: 10.21203/rs.3.rs-1638504/v1)

Hussain, S. A., Lester, J. F., Jackson, R., Gornall, M., Qureshi, M., Elliott, A., Crabb, S. J., Huddart, R. A., Vasudev, N., Birtle, A. J., Worlding, J., James, N. D., Parikh, O., Vilarino-Varela, M., Alonz, R., Linch, M. D., Riaz, I. B., Catto, J. W. F., Powles, T., Jones, R. J. (2022) Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial. Lancet Oncology, 23, pp. 650-658. (doi: 10.1016/S1470-2045(22)00158-9)

Rakovic, K., Colling, R., Browning, L., Dolton, M., Horton, M. R., Protheroe, A., Lamb, A. D., Bryant, R. J., Scheffer, R., Crofts, J., Stanislaus, E., Verrill, C. (2022) The use of digital pathology and artificial intelligence in histopathological diagnostic assessment of prostate cancer: a survey of Prostate Cancer UK supporters. Diagnostics, 12, (doi: 10.3390/diagnostics12051225)

Dinneen, E. et al. (2022) Negative mpMRI rules out extra-prostatic extension in prostate cancer before robot-assisted radical prostatectomy. Diagnostics, 12, (doi: 10.3390/diagnostics12051057)

Salji, M. J., Blomme, A., Däbritz, J. H. M., Repiscak, P., Lilla, S., Patel, R., Sumpton, D., Van Den Broek, N. J. F., Daly, R., Zanivan, S., Leung, H. Y. (2022) Multi-omics and pathway analysis identify potential roles for tumour n-acetyl aspartate accumulation in murine models of castration resistant prostate cancer. iScience, 25, (doi: 10.1016/j.isci.2022.104056)

Spiliopoulou, P., Spear, S., Mirza, H., Garner, I., Iyer, N., McGarry, L., Grundland-Freile, F., Cheng, Z., Ennis, D. P., McNamara, S., Natoli, M., Mason, S., Blyth, K., Adams, P. D., Roxburgh, P., Fuchter, M. J., Brown, B., McNeish, I. A. (2022) Dual G9A/EZH2 inhibition stimulates anti-tumour immune response in ovarian high grade serous carcinoma. Molecular Cancer Therapeutics, 21, pp. 522-534. (doi: 10.1158/1535-7163.MCT-21-0743)

Gómez, V., Galazi, M., Weitsman, G., Monypenny, J., Al-Salemee, F., Barber, P. R., Ng, K., Beatson, R., Szokol, B., Orfi, L., Mullen, G., Vanhaesebroeck, B., Chowdhury, S., Leung, H. Y., Ng, T. (2022) HER2 mediates PSMA/mGluR1-driven resistance to the DS-7423 dual PI3K/mTOR inhibitor in PTEN wild-type prostate cancer models. Molecular Cancer Therapeutics, 21, pp. 667-676. (doi: 10.1158/1535-7163.mct-21-0320)

O’Connell, S. P., Frantzi, M., Latosinska, A., Webb, M., Mullen, W., Pejchinovski, M., Salji, M., Mischak, H., Cooper, C. S., Clark, J., Brewer, D. S. (2022) A model to detect significant prostate cancer integrating urinary peptide and extracellular vesicle RNA data. Cancers, 14, (doi: 10.3390/cancers14081995)

Dunlop, E., Ferguson, A., Mueller, T., Baillie, K., Clarke, J., Laskey, J., Kurdi, A., Wu, O., Jones, R., Glen, H., Bennie, M. (2022) What matters to patients and clinicians when discussing the impact of cancer medicines on health-related quality of life? Consensus-based mixed methods approach in prostate cancer. Supportive Care in Cancer, 30, pp. 3141-3150. (doi: 10.1007/s00520-021-06724-6)

Gaba, F., Tipping, W. J., Salji, M., Faulds, K., Graham, D., Leung, H. Y. (2022) Raman spectroscopy in prostate cancer: techniques, applications and advancements. Cancers, 14, (doi: 10.3390/cancers14061535)

Fanfone, D., Wu, Z., Mammi, J., Berthenet, K., Neves, D., Weber, K., Halaburkova, A., Virard, F., Bunel, F., Jamard, C., Hernandez-Vargas, H., Tait, S. W.G., Hennino, A., Ichim, G. (2022) Confined migration promotes cancer metastasis through resistance to anoikis and increased invasiveness. eLife, 11, (doi: 10.7554/eLife.73150)

Blomme, A. et al. (2022) THEM6‐mediated reprogramming of lipid metabolism supports treatment resistance in prostate cancer. EMBO Molecular Medicine, 14, (doi: 10.15252/emmm.202114764)

Glen, C., Tan, Y. Y., Waterston, A., Evans, T. R. J., Jones, R. J., Petrie, M. C., Lang, N. N. (2022) Mechanistic and clinical overview cardiovascular toxicity of BRAF and MEK inhibitors: JACC: CardioOncology state-of-the-art review. JACC: CardioOncology, 4, pp. 1-18. (doi: 10.1016/j.jaccao.2022.01.096)

Humpton, T. J., Hall, H., Kiourtis, C., Nixon, C., Clark, W., Hedley, A., Shaw, R., Bird, T. G., Blyth, K., Vousden, K. H. (2022) p53-mediated redox control promotes liver regeneration and maintains liver function in response to CCl₄ Cell Death and Differentiation, 29, pp. 514-526. (doi: 10.1038/s41418-021-00871-3)

Humpton, T. J., Hock, A. K., Kiourtis, C., De Donatis, M., Fercoq, F., Nixon, C., Bryson, S., Strathdee, D., Carlin, L. M., Bird, T. G., Blyth, K., Vousden, K. (2022) A noninvasive iRFP713 p53 reporter reveals dynamic p53 activity in response to irradiation and liver regeneration in vivo. Science Signaling, 15, (doi: 10.1126/scisignal.abd9099)

Willers, H., Krause, M., Faivre-Finn, C., Chalmers, A. (2022) Targeting PARP for chemoradiosensitization: opportunities, challenges, and the road ahead. International Journal of Radiation Oncology, Biology, Physics, 112, pp. 265-270. (doi: 10.1016/j.ijrobp.2021.10.142)

Roman Fernandez, A., Sandilands, E., Bryant, D. M. (2022) The use of three-dimensional cell culture to study apicobasal polarization and lumen formation. Springer

Attard, G. et al. (2022) Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet, 399, pp. 447-460. (doi: 10.1016/S0140-6736(21)02437-5)

Adam, C., Bray, T. L., Pérez-López, A. M., Tan, E. H., Rubio-Ruiz, B., Baillache, D. J., Houston, D. R., Salji, M. J., Leung, H. Y., Unciti-Broceta, A. (2022) A 5-FU precursor designed to evade anabolic and catabolic drug pathways and activated by Pd chemistry in vitro and in vivo. Journal of Medicinal Chemistry, 65, pp. 552-561. (doi: 10.1021/acs.jmedchem.1c01733)

Jackson, M. R., Stevenson, K., Chahal, S. K., Curley, E., Finney, G. E., Gutierrez-Quintana, R., Onwubiko, E., Rupp, A., Strathdee, K., Williams, K., MacLeod, M. K.L., McSharry, C., Chalmers, A. J. (2022) Low-dose lung radiotherapy for COVID-19 lung disease: a preclinical efficacy study in a bleomycin model of pneumonitis. International Journal of Radiation Oncology, Biology, Physics, 112, pp. 197-211. (doi: 10.1016/j.ijrobp.2021.08.029)

Mueller, T., Laskey, J., Baillie, K., Clarke, J., Crearie, C., Kavanagh, K., Graham, J., Graham, K., Waterson, A., Jones, R., Kurdi, A., Morrison, D., Bennie, M. (2022) Opportunities and challenges when using record linkage of routinely collected electronic health care data to evaluate outcomes of systemic anti-cancer treatment in clinical practice. Health Informatics Journal, 28, pp. 14604582221077055. (doi: 10.1177/14604582221077055)

Aiyappa-Maudsley, R., Chalmers, A. J., Parsons, J. L. (2022) Factors affecting the radiation response in glioblastoma. Neuro-Oncology Advances, 4, (doi: 10.1093/noajnl/vdac156)

Gutierrez-Quintana, R., Walker, D. J., Williams, K. J., Forster, D. M., Chalmers, A. J. (2022) Radiation-induced neuroinflammation: a potential protective role for poly(ADP-ribose) polymerase inhibitors? Neuro-Oncology Advances, 4, (doi: 10.1093/noajnl/vdab190)

Derby, S. J., Chalmers, A. J., Carruthers, R. (2022) Radiotherapy-poly(ADP-ribose) polymerase inhibitor combinations: progress to date. Seminars in Radiation Oncology, 32, pp. 15-28. (doi: 10.1016/j.semradonc.2021.09.005)

Devlin, R., Roberts, E. (2022) Building a healthy mouse model ecosystem to interrogate cancer biology. Disease Models and Mechanisms, 15, (doi: 10.1242/dmm.049795)

Love, S. B. et al. (2022) Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units. Trials, 23, (doi: 10.1186/s13063-022-06680-4)

Rabas, N., Palmer, S., Mitchell, L., Ismail, S., Gohlke, A., Riley, J. S., Tait, S. W.G., Gammage, P., Lemgruber Soares, L., MacPherson, I. R., Norman, J. C. (2021) PINK1 drives production of mtDNA-containing extracellular vesicles to promote invasiveness. Journal of Cell Biology, 220, (doi: 10.1083/jcb.202006049)

Johnson, S. A., Ormsby, M. J., Wessel, H., Hulme, H., Bravo-Blas, A., McIntosh, A., Mason, S., Coffelt, S., Tait, S. W.G., Mcl. Mowat, A., Milling, S., Blyth, K., Wall, D. M. (2021) Monocytes mediate Salmonella Typhimurium-induced tumor growth inhibition in a mouse melanoma model. European Journal of Immunology, 51, pp. 3228-3238. (doi: 10.1002/eji.202048913)

Bock, F. J., Sedov, E., Koren, E., Koessinger, A. L., Cloix, C., Zerbst, D., Athineos, D., Anand, J., Campbell, K. J., Blyth, K., Fuchs, Y., Tait, S. W.G. (2021) Apoptotic stress-induced FGF signalling promotes non-cell autonomous resistance to cell death. Nature Communications, 12, (doi: 10.1038/s41467-021-26613-0)

McGarry, D. J., Armstrong, G., Castino, G., Mason, S., Clark, W., Shaw, R., McGarry, L., Blyth, K., Olson, M. F. (2021) MICAL1 regulates actin cytoskeleton organization, directional cell migration and the growth of human breast cancer cells as orthotopic xenograft tumours. Cancer Letters, 519, pp. 226-236. (doi: 10.1016/j.canlet.2021.07.039)

Birch, J., Strathdee, K., Stevenson, K., Derby, S., Dutton, L., Clough, E., Koessinger, A., Gilmour, L., McGhee, E., McGarrity-Cottrell, C., Dibekeme, A. a., Collis, S., Rominiyi, O., Lembruber Soares, L., Solecki, G., Winkler, F., Carlin, L., Inman, G., Chalmers, A., Norman, J., Carruthers, R. (2021) Inhibition of ATR prevents macropinocytosis driven retraction of neurites and opposes invasion in GBM. Research Square, (doi: 10.21203/rs.3.rs-967109/v1)

Tsim, S. et al. (2021) Serum proteomics and plasma fibulin-3 in differentiation of mesothelioma from asbestos-exposed controls and patients with other pleural diseases. Journal of Thoracic Oncology, 16, pp. 1705-1717. (doi: 10.1016/j.jtho.2021.05.018)

Halabi, S., Yang, Q., Carmack, A., Zhang, S., Foo, W.-C., Eisen, T., Stadler, W., Jones, R. J., Garcia, J., Picus, J., Hawkins, R., Hainsworth, J., Kollmannsberger, C., Logan, T., Puzanov, I., Pickering, L., Ryan, C., Protheroe, A., George, D., Armstrong, A. (2021) Tissue based biomarkers in non-clear cell RCC: Correlative analysis from the ASPEN clinical trial. Kidney Cancer Journal, 19, pp. 64-72. (doi: 10.52733/kcj19n3-a1)

Claudio Quiros, A., Coudray, N., Yeaton, A., Sunhem, W., Murray-Smith, R., Tsirigos, A., Yuan, K. (2021) Adversarial Learning of Cancer Tissue Representations. (doi: 10.1007/978-3-030-87237-3_58)

Campbell, K. J., Mason, S. M., Winder, M. L., Willemsen, R. B.E., Cloix, C., Lawson, H., Rooney, N., Dhayade, S., Sims, A. H., Blyth, K., Tait, S. W.G. (2021) Breast cancer dependence on MCL-1 is due to its canonical anti-apoptotic function. Cell Death and Differentiation, 28, pp. 2589-2600. (doi: 10.1038/s41418-021-00773-4)

Bao, J., Närhi, K., Teodòsio, A., Hemmes, A., Linnavirta, N. M., Mäyränpää, M. I., Salmenkivi, K., Le Quesne, J., Verschuren, E. W. (2021) SOX9 has distinct roles in the formation and progression of different non‐small cell lung cancer histotypes. Journal of Pathology, 255, pp. 16-29. (doi: 10.1002/path.5733)

Stonier, T. et al. (2021) The "Is mpMRI Enough" or IMRIE Study: a multicentre evaluation of prebiopsy multiparametric magnetic resonance imaging compared with biopsy. European Urology Focus, 7, pp. 1027-1034. (doi: 10.1016/j.euf.2020.09.012)

Massanova, M., Robertson, S., Barone, B., Butto, L., Caputo, V. F., Bhatt, J. R., Ahmad, I., Bada, M., Obeidallah, A., Crocetto, F. (2021) The comparison of imaging and clinical methods to estimate prostate volume: a single-centre retrospective study. Urologia Internationalis, 105, pp. 804-810. (doi: 10.1159/000516681)

Hanna, C. R., Robles-Zurita, J. A., Briggs, A., Harkin, A., Kelly, C., McQueen, J., Allan, K., Pearson, S., Hollander, N. H., Glimelius, B., Salazar, R., Segelov, E., Saunders, M., Iveson, T., Jones, R. J., Boyd, K. A. (2021) Three versus six months of adjuvant doublet chemotherapy for patients with colorectal cancer: a multi-country cost-effectiveness and budget impact analysis. Clinical Colorectal Cancer, 20, pp. 236-244. (doi: 10.1016/j.clcc.2021.04.001)

Marini, A. et al. (2021) The pathogenesis of mesothelioma is driven by a dysregulated translatome. Nature Communications, 12, (doi: 10.1038/s41467-021-25173-7)

Ghaddar, N., Wang, S., Woodvine, B., Krishnamoorthy, J., van Hoef, V., Darini, C., Kazimierczak, U., Ah-son, N., Popper, H., Johnson, M., Officer, L., Teodósio, A., Broggini, M., Mann, K. K., Hatzoglou, M., Topisirovic, I., Larsson, O., Le Quesne, J., Koromilas, A. E. (2021) The integrated stress response is tumorigenic and constitutes a therapeutic liability in KRAS-driven lung cancer. Nature Communications, 12, (doi: 10.1038/s41467-021-24661-0)

Ntala, C., Salji, M., Salmond, J., Officer, L., Teodosio, A. V., Blomme, A., McGhee, E. J., Powley, I., Ahmad, I., Kruithof-de Julio, M., Thalmann, G., Roberts, E., Goodyear, C. S., Jamaspishvili, T., Berman, D. M., Carlin, L. M., Le Quesne, J., Leung, H. Y. (2021) Analysis of prostate cancer tumor microenvironment identifies reduced stromal CD4 effector T-cell infiltration in tumors with pelvic nodal metastasis. European Urology Open Science, 29, pp. 19-29. (doi: 10.1016/j.euros.2021.05.001)

Welisch, G., Twelves, C., Plummer, R., Evans, J., Danson, S., Symeonides, S., Halsey, C., Jones, R., Hanna, C., Gallagher, P., Walls, G., Taylor, K., Barnett, S., Forde, C., White, M., Williams, C., El Badri, S., Chipole, B.'e. D., Keith, N. (2021) First in Human: who and what makes a cancer phase 1 trial and why are they so important? (doi: 10.17605/OSF.IO/KWHQF)

Martinez, R. S., Salji, M. J., Rushworth, L., Ntala, C., Rodriguez Blanco, G., Hedley, A., Clark, W., Peixoto, P., Hervouet, E., Renaude, E., Kung, S. H. Y., Galbraith, L. C.A., Nixon, C., Lilla, S., Mackay, G. M., Fazli, L., Gaughan, L., Sumpton, D., Gleave, M. E., Zanivan, S., Blomme, A., Leung, H. Y. (2021) SLFN5 regulates LAT1-mediated mTOR activation in castration-resistant prostate cancer. Cancer Research, 81, pp. 3664-3678. (doi: 10.1158/0008-5472.CAN-20-3694)

Nászai, M., Bellec, K., Yu, Y., Román-Fernández, Á., Sandilands, E., Johansson, J., Campbell, A. D., Norman, J. C., Sansom, O. J., Bryant, D. M., Cordero, J. B. (2021) RAL GTPases mediate EGFR-driven intestinal stem cell proliferation and tumourigenesis. eLife, 10, (doi: 10.7554/eLife.63807)

Koessinger, A. L., Koessinger, D., Kinch, K., Martínez-Escardó, L., Paul, N. R., Elmasry, Y., Malviya, G., Cloix, C., Campbell, K. J., Bock, F. J., O'Prey, J., Stevenson, K., Nixon, C., Jackson, M. R., Ichim, G., Stewart, W., Blyth, K., Ryan, K. M., Chalmers, A. J., Norman, J. C., Tait, S. W.G. (2021) Increased apoptotic priming of glioblastoma enables therapeutic targeting by BH3-mimetics. bioRxiv, (doi: 10.1101/2021.06.13.448232)

Newman, A. C., Falcone, M., Huerta Uribe, A., Zhang, T., Athineos, D., Pietzke, M., Vazquez, A., Blyth, K., Maddocks, O. D. K. (2021) Immune regulated IDO1-dependent tryptophan metabolism is source of one-carbon units for pancreatic cancer and stellate cells. Molecular Cell, 81, pp. 2290-2302.e7. (doi: 10.1016/j.molcel.2021.03.019)

Armstrong, A. J., Nixon, A. B., Carmack, A., Eisen, T., Stadler, W. M., Jones, R. J., Garcia, J. A., Vaishampayan, U. N., Picus, J., Hawkins, R. E., Hainsworth, J. D., Kollmannsberger, C. K., Logan, T. F., Puzanov, I., Pickering, L. M., Ryan, C. W., Protheroe, A., George, D. J., Halabi, S. (2021) Angiokines associated with outcomes after sunitinib or everolimus treatment in patients with non-clear cell renal cell carcinoma. Clinical Cancer Research, 27, pp. 3317-3328. (doi: 10.1158/1078-0432.CCR-20-4504)

Nile, D. L., Rae, C., Walker, D. J., Canning Waddington, J., Vincent, I., Burgess, K., Gaze, M. N., Mairs, R. J., Chalmers, A. J. (2021) Inhibition of glycolysis and mitochondrial respiration promotes radiosensitisation of neuroblastoma and glioma cells. Cancer and Metabolism, 9, (doi: 10.1186/s40170-021-00258-5)

Powles, T., Carroll, D., Chowdhury, S., Gravis, G., Joly, F., Carles, J., Fléchon, A., Maroto, P., Petrylak, D., Rolland, F., Cook, N., Balar, A. V., Sridhar, S. S., Galsky, M. D., Grivas, P., Ravaud, A., Jones, R., Cosaert, J., Hodgson, D., Kozarewa, I., Mather, R., McEwen, R., Mercier, F., Landers, D. (2021) An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer. Nature Medicine, 27, pp. 793-801. (doi: 10.1038/s41591-021-01317-6)

Cangiano, M., Grudniewska, M., Salji, M. J., Nykter, M., Jenster, G., Urbanucci, A., Grabcgu, Z., Janssen, B., Hamilton, G., Leung, H. Y., Beumer, I. J. (2021) Gene regulation network analysis on human prostate orthografts highlights a potential role for the JMJD6 regulon in clinical prostate cancer. Cancers, 13, (doi: 10.3390/cancers13092094)

Sereno, M., He, Z., Smith, C. R., Baena, J., Das, M., Hastings, R. K., Rake, G., Fennell, D. A., Nakas, A., Moore, D. A., Le Quesne, J. (2021) Inclusion of multiple high‐risk histopathological criteria improves the prediction of adjuvant chemotherapy efficacy in lung adenocarcinoma. Histopathology, 78, pp. 838-848. (doi: 10.1111/his.14301)

Knight, J. R.P. et al. (2021) MNK inhibition sensitizes KRAS-mutant colorectal cancer to mTORC1 inhibition by reducing eIF4E phosphorylation and c-MYC expression. Cancer Discovery, 11, pp. 1228-1247. (doi: 10.1158/2159-8290.CD-20-0652)

Chalmers, A.J., Carruthers, R.D. (2021) Radiobiology summaries: DNA damage and repair. Clinical Oncology, 33, pp. 275-278. (doi: 10.1016/j.clon.2020.12.006)

Galbraith, L. C.A., Mui, E., Nixon, C., Hedley, A., Strachan, D., MacKay, G., Sumpton, D., Sansom, O. J., Leung, H. Y., Ahmad, I. (2021) PPAR-gamma induced AKT3 expression increases levels of mitochondrial biogenesis driving prostate cancer. Oncogene, 40, pp. 2355-2366. (doi: 10.1038/s41388-021-01707-7)

Busacca, S., Zhang, Q., Sharkey, A., Dawson, A. G., Moore, D. A., Waller, D. A., Nakas, A., Jones, C., Cain, K., Luo, J.-l., Salcedo, A., Salaroglio, I. C., Riganti, C., Le Quesne, J., John, T., Boutros, P. C., Zhang, S.-D., Fennell, D. A. (2021) Transcriptional perturbation of protein arginine methyltransferase-5 exhibits MTAP-selective oncosuppression. Scientific Reports, 11, (doi: 10.1038/s41598-021-86834-7)

Roca-Portoles, A., Tait, S. W.G. (2021) Mitochondrial quality control: from molecule to organelle. Cellular and Molecular Life Sciences, 78, pp. 3853-3866. (doi: 10.1007/s00018-021-03775-0)

Hanna, C., Lemmon, E., Ennis, H., Jones, R., Hay, J., Halliday, R., Clark, S., Morris, E., Hall, P. (2021) Creation of the first national linked colorectal cancer dataset in Scotland: prospects for future research and a reflection on lessons learned. International Journal of Population Data Science, 6, (doi: 10.23889/ijpds.v6i1.1654)

Claudio Quiros, A., Murray-Smith, R., Yuan, K. (2021) PathologyGAN: Learning deep representations of cancer tissue. Journal of Machine Learning for Biomedical Imaging, 2021, pp. 1-48.

Zhang, M. et al. (2021) Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment. Nature Communications, 12, (doi: 10.1038/s41467-021-21798-w)

Hanna, C. R., Robb, K. A., Blyth, K. G., Jones, R. J., Chalmers, A. J. (2021) Clinician attitudes to using low dose radiotherapy to treat COVID-19 lung disease. International Journal of Radiation Oncology, Biology, Physics, 109, pp. 886-890. (doi: 10.1016/j.ijrobp.2020.12.003)

Nacke, M., Sandilands, E., Nikolatou, K., Román-Fernández, Á., Mason, S., Patel, R., Lilla, S., Yelland, T., Galbraith, L. C.A., Freckmann, E. C., McGarry, L., Morton, J. P., Shanks, E., Leung, H. Y., Markert, E., Ismail, S., Zanivan, S., Blyth, K., Bryant, D. M. (2021) An ARF GTPase module promoting invasion and metastasis through regulating phosphoinositide metabolism. Nature Communications, 12, (doi: 10.1038/s41467-021-21847-4)

Hanna, C. R., Boyd, K. A., Jones, R. J. (2021) Evaluating cancer research impact: lessons and examples from existing reviews on approaches to research impact assessment. Health Research Policy and Systems, 19, (doi: 10.1186/s12961-020-00658-x)

Annese, V. F., Patil, S. B., Hu, C., Giagkoulovits, C., Al-Rawhani, M. A., Grant, J., Macleod, M., Clayton, D.J., Heaney, L.M., Daly, R., Accarino, C., Shah, Y. D., Cheah, B. C., Beeley, J., Evans, T.R.J., Jones, R., Barrett, M. P., Cumming, D. R.S. (2021) A monolithic single-chip point-of-care platform for metabolomic prostate cancer detection. Microsystems and Nanoengineering, 7, (doi: 10.1038/s41378-021-00243-4)

Rulach, R., Ball, D., Chua, K., Dahele, M., De Ruysscher, D., Franks, K., Gomez, D., Guckenberger, M., Hanna, G., Louie, A., Moghanaki, D., Palma, D., Peedell, C., Salem, A., Silva, S., Videtic, G., Chalmers, A., Harrow, S. (2021) An international expert survey on the indications and practice of radical thoracic reirradiation for non-small cell lung cancer. Advances in Radiation Oncology, 6, (doi: 10.1016/j.adro.2021.100653)

Phatak, V., von Grabowiecki, Y., Janus, J., Officer, L., Behan, C., Aschauer, L., Pinon, L., Mackay, H., Zanivan, S., Norman, J. C., Kelly, M., Le Quesne, J., Muller, P. A. J. (2021) Mutant p53 promotes RCP-dependent chemoresistance coinciding with increased delivery of P-glycoprotein to the plasma membrane. Cell Death and Disease, 12, (doi: 10.1038/s41419-021-03497-y)

Laskar, P., Somani, S., Mullin, M., Tate, R. J., Warzecha, M., Bowering, D., Keating, P., Irving, C., Leung, H. Y., Dufès, C. (2021) Octadecyl chain-bearing PEGylated poly(propyleneimine)-based dendrimersomes: physicochemical studies, redox-responsiveness, DNA condensation, cytotoxicity and gene delivery to cancer cells. Biomaterials Science, 9, pp. 1431-1448. (doi: 10.1039/D0BM01441A)

Liu, Q., Palomero, L., Moore, J., Guiz, I., Espín, R., Aytés, A., Mao, J.-H., Paulovich, A. G., Whiteaker, J. R., Ivey, R. G., Iliakis, G., Luo, D., Chalmers, A. J., Murnane, J., Pujana, M. A., Barcellos-Hoff, M. H. (2021) Loss of TGFβ signaling increases alternative end-joining DNA repair that sensitizes to genotoxic therapies across cancer types. Science Translational Medicine, 13, (doi: 10.1126/scitranslmed.abc4465)

Hartley, A., Leung, H. Y., Ahmad, I. (2021) Targeting the BAF complex in advanced prostate cancer. Expert Opinion on Drug Discovery, 16, pp. 173-181. (doi: 10.1080/17460441.2020.1821644)

Jensen, M. P., Le Quesne, J., Officer‐Jones, L., Teodòsio, A., Thaventhiran, J., Ficken, C., Goddard, M., Smith, C., Menon, D., Allinson, K. S. J. (2021) Neuropathological findings in two patients with fatal COVID‐19. Neuropathology and Applied Neurobiology, 47, pp. 17-25. (doi: 10.1111/nan.12662)

Crabb, S. J., Griffiths, G., Marwood, E., Dunkley, D., Downs, N., Martin, K., Light, M., Northey, J., Wilding, S., Whitehead, A., Shaw, E., Birtle, A. J., Bahl, A., Elliott, T., Westbury, C., Sundar, S., Robinson, A., Jagdev, S., Kumar, S., Rooney, C., Salinas-Souza, C., Stephens, C., Khoo, V., Jones, R. J. (2021) Pan-AKT inhibitor capivasertib with docetaxel and prednisolone in metastatic castration-resistant prostate cancer: a randomized, placebo-controlled phase II trial (ProCAID) Journal of Clinical Oncology, 39, pp. 190-201. (doi: 10.1200/JCO.20.01576)

Tajan, M., Hennequart, M., Cheung, E. C., Zani, F., Hock, A. K., Legrave, N., Maddocks, O. D.K., Ridgway, R. A., Athineos, D., Suárez-Bonnet, A., Ludwig, R. L., Novellasdemunt, L., Angelis, N., Li, V. S.W., Vlachogiannis, G., Valeri, N., Mainolfi, N., Suri, V., Friedman, A., Manfredi, M., Blyth, K., Sansom, O. J., Vousden, K. H. (2021) Serine synthesis pathway inhibition cooperates with dietary serine and glycine limitation for cancer therapy. Nature Communications, 12, (doi: 10.1038/s41467-020-20223-y)

Latif, A.-L. et al. (2021) BRD4-mediated repression of p53 is a target for combination therapy in AML. Nature Communications, 12, (doi: 10.1038/s41467-020-20378-8)

Humpton, T. J., Nomura, K., Weber, J., Magnussen, H. M., Hock, A. K., Nixon, C., Dhayade, S., Stevenson, D., Huang, D. T., Strathdee, D., Blyth, K., Vousden, K. H. (2021) Differential requirements for MDM2 E3 activity during embryogenesis and in adult mice. Genes and Development, 35, pp. 117-132. (doi: 10.1101/gad.341875.120)

Al-mubarak, H., Vallatos, A., Gallagher, L., Birch, J., Chalmers, A.J., Holmes, W.M. (2021) Evaluating potential of multi-parametric MRI using co-registered histology: Application to a mouse model of glioblastoma. Magnetic resonance imaging, 85, pp. 121-127. (doi: 10.1016/j.mri.2021.10.030)

Hadjiyiannakis, D., Dimitroyannis, D., Eastlake, L., Peedell, C., Tripathi, L., Simcock, R., Vyas, A., Deutsch, E., Chalmers, A.J. (2021) Personal view: low-dose lung radiotherapy should be evaluated as a treatment for severe COVID-19 lung disease. Clinical Oncology, 33, pp. e64-e68. (doi: 10.1016/j.clon.2020.08.003)

Dentro, S. C. et al. (2021) Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes. Cell, 184, pp. 2239-2254.e39. (doi: 10.1016/j.cell.2021.03.009)

Hanna, C. R., Boyd, K. A., Wincenciak, J., Graham, J., Iveson, T., Jones, R. J., Wilson, R. (2021) Do clinical trials change practice? A longitudinal, international assessment of colorectal cancer prescribing practices. Cancer Treatment and Research Communications, 28, (doi: 10.1016/j.ctarc.2021.100445)

Macintyre, G., Piskorz, A. M., Berman, A., Ross, E., Morse, D. B., Yuan, K., Ennis, D., Pike, J. A., Goranova, T., Mcneish, I. A., Brenton, J. D., Markowetz, F. (2021) FrenchFISH: Poisson Models for Quantifying DNA Copy Number From Fluorescence In Situ Hybridization of Tissue Sections. JCO Clinical Cancer Informatics, 5, pp. 176-186. (doi: 10.1200/cci.20.00075)

Klionsky, D. J. et al. (2021) Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition) Autophagy, 17, pp. 1-382. (doi: 10.1080/15548627.2020.1797280)

Valtonen, S., Vuorinen, E., Kariniemi, T., Eskonen, V., Le Quesne, J., Bushell, M., Härmä, H., Kopra, K. (2020) Nanomolar Protein-Protein Interaction monitoring with a label-free protein-probe technique. Analytical chemistry, 92, pp. 15781-15788. (doi: 10.1021/acs.analchem.0c02823)

Claudio Quiros, A., Murray-Smith, R., Yuan, K. (2020) Learning a Low Dimensional Manifold of Real Cancer Tissue with PathologyGAN.

McAllister, M. J., McCall, P., Dickson, A., Underwood, M. A., Andersen, D., Holmes, E., Market, E., Leung, H. Y., Edwards, J. (2020) Androgen receptor phosphorylation at serine 81 and serine 213 in castrate-resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 23, pp. 596-606. (doi: 10.1038/s41391-020-0235-1)

Hanna, C., Kurian, K. M., Williams, K., Watts, C., Jackson, A., Carruthers, R., Strathdee, K., Cruickshank, G., Dunn, L., Erridge, S., Godfrey, L., Jefferies, S., McBain, C., Sleigh, R., McCormick, A., Pittman, M., Halford, S., Chalmers, A. J. (2020) Pharmacokinetics, safety and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial. Neuro-Oncology, 22, pp. 1840-1850. (doi: 10.1093/neuonc/noaa104)

Ahmed, A., Tait, S. W.G. (2020) Targeting immunogenic cell death in cancer. Molecular Oncology, 14, pp. 2994-3006. (doi: 10.1002/1878-0261.12851)

Malviya, G., Patel, R., Salji, M., Martinez, R. S., Repiscak, P., Mui, E., Champion, S., Mrowinska, A., Johnson, E., AlRasheedi, M., Pimlott, S., Lewis, D., Leung, H. Y. (2020) 18F-Fluciclovine PET metabolic imaging reveals prostate cancer tumour heterogeneity associated with disease resistance to androgen deprivation therapy. EJNMMI Research, 10, (doi: 10.1186/s13550-020-00728-9)

Hanna, C. R., Blyth, K. G., Burley, G., Carmichael, S., Evans, C., Hinsley, S., Khadra, I., Khoo, S., Lewsley, L.-A., Jones, R. R., Sharma, R., Taladriz-Sender, A., Thomson, E. C., Scott, J. T. (2020) Glasgow Early Treatment Arm Favirpiravir (GETAFIX) for adults with early stage COVID-19: A structured summary of a study protocol for a randomised controlled trial. Trials, 21, (doi: 10.1186/s13063-020-04891-1)

Fercoq, F., Remion, E., Vallarino-Lhermitte, N., Alonso, J., Raveendran, L., Nixon, C., Le Quesne, J., Carlin, L. M., Martin, C. (2020) Microfilaria-dependent thoracic pathology associated with eosinophilic and fibrotic polyps in filaria-infected rodents. Parasites and Vectors, 13, (doi: 10.1186/s13071-020-04428-0)

McAllister, M., Constancio, V., Patek, S., Gan, H., Bailey, P., Wheadon, H., Underwood, M., Leung, H., Edwards, J. (2020) Inflammatory infiltration is associated with AR expression and poor prognosis in hormone naïve prostate cancer. Prostate, 80, pp. 1353-1364. (doi: 10.1002/pros.24064)

Stöhr, D., Schmid, J. O., Beigl, T. B., Mack, A., Maichl, D. S., Cao, K., Budai, B., Fullstone, G., Kontermann, R. E., Mürdter, T. E., Tait, S. W.G., Hagenlocher, C., Pollak, N., Scheurich, P., Rehm, M. (2020) Stress-induced TRAILR2 expression overcomes TRAIL resistance in cancer cell spheroids. Cell Death and Differentiation, 27, pp. 3037-3052. (doi: 10.1038/s41418-020-0559-3)

Mevel, R., Steiner, I., Mason, S., Galbraith, L. C.A., Patel, R., Fadlullah, M. Z.H., Ahmad, I., Leung, H. Y., Oliveira, P., Blyth, K., Baena, E., Lacaud, G. (2020) RUNX1 marks a luminal castration-resistant lineage established at the onset of prostate development. eLife, 9, (doi: 10.7554/elife.60225)

Mariappan, P., Johnston, A., Padovani, L., Clark, E., Trail, M., Hamid, S., Hollins, G., Simpson, H., Thomas, B. G., Hasan, R., Bhatt, J., Ahmad, I., Nandwani, G. M., Mitchell, I. D.C., Hendry, D. (2020) Enhanced quality and effectiveness of transurethral resection of bladder tumour in non–muscle-invasive bladder cancer: a multicentre real-world experience from Scotland’s Quality Performance Indicators programme. European Urology, 78, pp. 520-530. (doi: 10.1016/j.eururo.2020.06.051)

Zhang, T., Bauer, C., Newman, A. C., Uribe, A. H., Athineos, D., Blyth, K., Maddocks, O. D.K. (2020) Polyamine pathway activity promotes cysteine essentiality in cancer cells. Nature Metabolism, 2, pp. 1062-1076. (doi: 10.1038/s42255-020-0253-2)

Claudio Quiros, A., Murray-Smith, R., Yuan, K. (2020) PathologyGAN: Learning Deep Representations of Cancer Tissue.

Koessinger, A. L., Koessinger, D., Stevenson, K., Cloix, C., Mitchell, L., Nixon, C., Gomez-Roman, N., Chalmers, A. J., Norman, J. C., Tait, S. W.G. (2020) Quantitative in vivo bioluminescence imaging of orthotopic patient-derived glioblastoma xenografts. Scientific Reports, 10, (doi: 10.1038/s41598-020-72322-x)

Bailey, M. H. et al. (2020) Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples. Nature Communications, 11, (doi: 10.1038/s41467-020-18151-y)

Hall, P. E., Shepherd, S. T.C., Brown, J., Larkin, J., Jones, R., Ralph, C., Hawkins, R., Chowdhury, S., Boleti, E., Bahl, A., Fife, K., Webb, A., Crabb, S. J., Geldart, T., Hill, R., Dunlop, J., McLaren, D., Ackerman, C., Wimalasingham, A., Beltran, L., Nathan, P., Powles, T. (2020) Radiological response heterogeneity is of prognostic significance in metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. European Urology Focus, 6, pp. 999-1005. (doi: 10.1016/j.euf.2019.01.010)

Rae, C., Fragkoulis, G. I., Chalmers, A. J. (2020) Cytotoxicity and radiosensitizing activity of the fatty acid synthase inhibitor C75 is enhanced by blocking fatty acid uptake in prostate cancer cells. Advances in Radiation Oncology, 5, pp. 944-1005. (doi: 10.1016/j.adro.2020.06.022)

Pritchard, J. J.G., Hamilton, G., Hurst, C. D., Fraser, S., Orange, C., Knowles, M. A., Jones, R. J., Leung, H. Y., Iwata, T. (2020) Monitoring of urothelial cancer disease status after treatment by digital droplet PCR liquid biopsy assays. Urologic Oncology: Seminars and Original Investigations, 38, pp. 731.e1-737.e10. (doi: 10.1016/j.urolonc.2020.05.012)

Dinneen, E., Haider, A., Freeman, A., Oxley, J., Briggs, T., Nathan, S., Kelly, J., Grierson, J., Allen, C., Persad, R., Aning, J., Oakley, N., Ahmad, I., Dutto, L., Shaw, G. (2020) NeuroSAFE PROOF randomised controlled feasibility study: brief report of perioperative outcomes, histological concordance, and feasibility. European Urology, 78, pp. 476-478. (doi: 10.1016/j.eururo.2020.03.052)

Li, C. H. et al. (2020) Sex differences in oncogenic mutational processes. Nature Communications, 11, (doi: 10.1038/s41467-020-17359-2)

Roca Portoles, A., Blanco, G., Sumpton, D., Cloix, C., Mullin, M., Mackay, G. M., O'Neill, K., Lemgruber Soares, L., Luo, X., Tait, S. W.G. (2020) Venetoclax causes metabolic reprogramming independent of BCL-2 inhibition. Cell Death and Disease, 11, (doi: 10.1038/s41419-020-02867-2)

Jones, R., Crabb, S., Chester, J., Elliott, T., Huddart, R., Birtle, A., Evans, L., Lester, J., Jagdev, S., Casbard, A., Huang, C., Madden, T.-A., Griffiths, G. (2020) A randomised phase II trial of carboplatin and gemcitabine +/- vandetanib in first line treatment of advanced urothelial cell cancer patients not suitable to receive cisplatin. BJU International, 126, pp. 292-299. (doi: 10.1111/bju.15096)

Curtin, N., Bányai, K., Thaventhiran, J., Le Quesne, J., Helyes, Z., Bai, P. (2020) Repositioning PARP inhibitors for SARS‐CoV‐2 infection(COVID‐19); a new multi‐pronged therapy for acute respiratory distress syndrome? British Journal of Pharmacology, 177, pp. 3635-3645. (doi: 10.1111/bph.15137)

Millar, R., Kilbey, A., Remak, S.-J., Severson, T. M., Dhayade, S., Sandilands, E., Foster, K., Bryant, D. M., Blyth, K., Coffelt, S. B. (2020) The MSP-RON axis stimulates cancer cell growth in models of triple negative breast cancer. Molecular Oncology, 14, pp. 1868-1880. (doi: 10.1002/1878-0261.12734)

Dhayade, S., Pietzke, M., Wiesheu, R., Tait-Mulder, J., Athineos, D., Sumpton, D., Coffelt, S., Blyth, K., Vazquez, A. (2020) Impact of formate supplementation on body weight and plasma amino acids. Nutrients, 12, (doi: 10.3390/nu12082181)

Lewis, R., Todd, R., Newton, M., Jones, R. J., Wilson, C., Donovan, J. L., Bryan, R. T., Birtle, A., Hall, E. (2020) The implementation and utility of patient screening logs in a multicentre randomised controlled oncology trial. Trials, 21, (doi: 10.1186/s13063-020-04559-w)

Dobbin, S. J.H., Mangion, K., Berry, C., Roditi, G., Basak, S., Sourbron, S., White, J., Venugopal, B., Touyz, R. M., Jones, R. J., Petrie, M. C., Lang, N. N. (2020) Cardiotoxicity and myocardial hypoperfusion associated with anti-VEGF therapies: prospective cardiac magnetic resonance imaging in patients with cancer. European Journal of Heart Failure, 22, pp. 1276-1277. (doi: 10.1002/ejhf.1847)

AbdulJabbar, K. et al. (2020) Geospatial immune variability illuminates differential evolution of lung adenocarcinoma. Nature Medicine, 26, pp. 1054-1062. (doi: 10.1038/s41591-020-0900-x)

Rana, D., Geue, C., Baillie, K., Pan, J., Mueller, T., Laskey, J., Bennie, M., Clarke, J., Jones, R. J., Brown, A., Wu, O. (2020) Healthcare Costs for Metastatic Castration Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide in the Pre and Post Chemotherapy Setting.

Hanna, C. R., Gatting, L. P., Boyd, K. A., Robb, K. A., Jones, R. J. (2020) Evidencing the impact of cancer trials: insights from the 2014 UK Research Excellence Framework. Trials, 21, (doi: 10.1186/s13063-020-04425-9)

Rooney, N., Mason, S. M., McDonald, L., Däbritz, J. H. M., Campbell, K. J., Hedley, A., Howard, S., Athineos, D., Nixon, C., Clark, W., Leach, J. D., Sansom, O. J., Edwards, J., Cameron, E. R., Blyth, K. (2020) RUNX1 is a driver of renal cell carcinoma correlating with clinical outcome. Cancer Research, 80, pp. 2325-2339. (doi: 10.1158/0008-5472.CAN-19-3870)

Baillie, K., Mueller, T., Pan, J., Laskey, J., Bennie, M., Crearie, C., Kavanagh, K., Alvarez‐Madrazo, S., Morrison, D., Clarke, J., Keel, A., Cameron, D., Wu, O., Kurdi, A., Jones, R. J. (2020) Use of record linkage to evaluate treatment outcomes and trial eligibility in a real‐world metastatic prostate cancer population in Scotland. Pharmacoepidemiology and Drug Safety, 29, pp. 653-663. (doi: 10.1002/pds.4998)

Blomme, A. et al. (2020) 2,4-dienoyl-CoA reductase regulates lipid homeostasis in treatment-resistant prostate cancer. Nature Communications, 11, (doi: 10.1038/s41467-020-16126-7)

Kos, Z. et al. (2020) Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. npj Breast Cancer, 6, (doi: 10.1038/s41523-020-0156-0)

Scarsbrook, A. F., Bottomley, D., Teoh, E. J., Bradley, K. M., Payne, H., Afaq, A., Bomanji, J., van As, N., Chua, S., Hoskin, P., Chambers, A., Cook, G. J., Warbey, V. S., Han, S., Leung, H. Y., Chau, A., Miller, M. P., Gleeson, F. V., on behalf of the FALCON Study Group, . (2020) Effect of 18F-fluciclovine positron emission tomography on the management of patients with recurrence of prostate cancer: Results from the FALCON Trial. International Journal of Radiation Oncology, Biology, Physics, 107, pp. 316-324. (doi: 10.1016/j.ijrobp.2020.01.050)

Litchfield, K. et al. (2020) Representative sequencing: unbiased sampling of solid tumor tissue. Cell Reports, 31, (doi: 10.1016/j.celrep.2020.107550)

Oizel, K., Tait-Mulder, J., Fernandez-de-Cossio-Diaz, J., Pietzke, M., Brunton, H., Lilla, S., Dhayade, S., Athineos, D., Blanco, G. R., Sumpton, D., Mackay, G. M., Blyth, K., Zanivan, S. R., Meiser, J., Vazquez, A. (2020) Formate induces a metabolic switch in nucleotide and energy metabolism. Cell Death and Disease, 11, (doi: 10.1038/s41419-020-2523-z)

Fulton, B., Jones, R., Powles, T., Crabb, S., Paul, J., Birtle, A., Chowdhury, S., Hussain, S., Morris, A., Soulis, E., Morrison, P. (2020) ATLANTIS: a randomised multi-arm phase II biomarker-directed umbrella screening trial of maintenance targeted therapy after chemotherapy in patients with advanced or metastatic urothelial cancer. Trials, 21, (doi: 10.1186/s13063-020-04283-5)

Birtle, A., Johnson, M., Chester, J., Jones, R., Dolling, D., Bryan, R. T., Harris, C., Winterbottom, A., Blacker, A., Catto, J. W.F., Chakraborti, P., Donovan, J. L., Elliott, P. A., French, A., Jagdev, S., Jenkins, B., Keeley, F. X., Kockelbergh, R., Powles, T., Wagstaff, J., Wilson, C., Todd, R., Lewis, R., Hall, E. (2020) Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. Lancet, 395, pp. 1268-1277. (doi: 10.1016/S0140-6736(20)30415-3)

Riley, J. S., Tait, S. W.G. (2020) Mitochondrial DNA in inflammation and immunity. EMBO Reports, 21, (doi: 10.15252/embr.201949799)

Campbell, K. J., Blyth, K. (2020) Somatic base editing to model oncogenic drivers in breast cancer. Lab Animal, 49, pp. 115-116. (doi: 10.1038/s41684-020-0510-8)

Gonzalez‐Ericsson, P. I. et al. (2020) The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers in breast cancer clinical trials and daily practice. Journal of Pathology, 250, pp. 667-684. (doi: 10.1002/path.5406)

Jackson, M. R., Ashton, M., Koessinger, A. L., Dick, C., Verheij, M., Chalmers, A. J. (2020) Mesothelioma cells depend on the anti-apoptotic protein Bcl-xL for survival and are sensitized to ionizing radiation by BH3-mimetics. International Journal of Radiation Oncology, Biology, Physics, 106, pp. 867-877. (doi: 10.1016/j.ijrobp.2019.11.029)

Neal, D. E. et al. (2020) Ten-year mortality, disease progression, and treatment-related side effects in men with localised prostate cancer from the ProtecT Randomised Controlled Trial according to treatment received. European Urology, 77, pp. 320-330. (doi: 10.1016/j.eururo.2019.10.030)

Sweeney, K., Cameron, E. R., Blyth, K. (2020) Complex interplay between the RUNX transcription factors and Wnt/β-catenin pathway in cancer: a tango in the night. Molecules and Cells, 43, pp. 188-197. (doi: 10.14348/molcells.2019.0310)

Lie-A-Ling, M., Mevel, R., Patel, R., Blyth, K., Baena, E., Kouskoff, V., Lacaud, G. (2020) RUNX1 dosage in development and cancer. Molecules and Cells, 43, pp. 126-138. (doi: 10.14348/molcells.2019.0301)

MacKenzie, D. J., Robertson, N. A., Rather, I., Reid, C., Sendzikaite, G., Cruickshanks, H., McBryan, T., Hodges, A., Pritchard, C., Blyth, K., Adams, P. D. (2020) DNMT3B Oncogenic Activity in Human Intestinal Cancer Is Not Linked to CIMP or BRAFV600E Mutation. iScience, 23, (doi: 10.1016/j.isci.2020.100838)

Rushworth, L. K., Hewit, K., Munnings-Tomes, S., Somani, S., James, D., Shanks, E., Dufès, C., Straube, A., Patel, R., Leung, H. Y. (2020) Repurposing screen identifies mebendazole as a clinical candidate to synergise with docetaxel for prostate cancer treatment. British Journal of Cancer, 122, pp. 517-527. (doi: 10.1038/s41416-019-0681-5)

Cheung, E. C., DeNicola, G. M., Nixon, C., Blyth, K., Labuschagne, C. F., Tuveson, D. A., Vousden, K. (2020) Dynamic ROS control by TIGAR regulates the initiation and progression of pancreatic cancer. Cancer Cell, 37, pp. 168-182.e4. (doi: 10.1016/j.ccell.2019.12.012)

The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, , Bailey, P. J., Chang, D. K., Cooke, S. L., Biankin, A. V., Duthie, F. R., Graham, J. S., Jamieson, N. B., Musgrove, E. A., Martin, S., Yuan, K., Wright, D. W., Oien, K. A. (2020) Pan-cancer analysis of whole genomes. Nature, 578, pp. 82-93. (doi: 10.1038/s41586-020-1969-6)

Gerstung, M. et al. (2020) The evolutionary history of 2,658 cancers. Nature, 578, pp. 122-128. (doi: 10.1038/s41586-019-1907-7)

Cmero, M., Yuan, K., Ong, C. S., Schröder, J., PCAWG Evolution and Heterogeneity Working Group, , Corcoran, N. M., Papenfuss, T., Hovens, C. M., Markowetz, F., Macintyre, G., PCAWG Consortium, (2020) Inferring structural variant cancer cell fraction. Nature Communications, 11, (doi: 10.1038/s41467-020-14351-8)

Rubanova, Y., Shi, R., Harrigan, C. F., Li, R., Wintersinger, J., Sahin, N., Deshwar, A., Morris, Q. (2020) Reconstructing evolutionary trajectories of mutation signature activities in cancer using TrackSig. Nature Communications, 11, (doi: 10.1038/s41467-020-14352-7)

Patel, R., Brzezinska, E. A., Repiscak, P., Ahmad, I., Mui, E., Gao, M., Blomme, A., Harle, V., Tan, E. H., Malviya, G., Mrowinska, A., Loveridge, C. J., Rushworth, L. K., Edwards, J., Ntala, C., Nixon, C., Hedley, A., Mackay, G., Tardito, S., Sansom, O. J., Leung, H. Y. (2020) Activation of β-catenin cooperates with loss of Pten to drive AR-independent castration-resistant prostate cancer. Cancer Research, 80, pp. 576-590. (doi: 10.1158/0008-5472.CAN-19-1684)

Witjes, J. A. et al. (2020) EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multistakeholder effort† EU*ACME: under the auspices of the EAU-ESMO guidelines committees. European Urology, 77, pp. 223-250. (doi: 10.1016/j.eururo.2019.09.035)

Gomez-Roman, N., Chong, M. Y., Chahal, S. K., Caragher, S. P., Jackson, M. R., Stevenson, K. H., Dongre, S. A., Chalmers, A. J. (2020) Radiation responses of 2D and 3D glioblastoma cells: a novel, 3D-specific radioprotective role of VEGF/Akt signaling through functional activation of NHEJ. Molecular Cancer Therapeutics, 19, pp. 575-589. (doi: 10.1158/1535-7163.MCT-18-1320)

Caraffini, V., Geiger, O., Rosenberger, A., Hatzl, S., Perfler, B., Berg, J. L., Lim, C., Strobl, H., Kashofer, K., Schauer, S., Beham-Schmid, C., Hoefler, G., Geissler, K., Quehenberger, F., Kolch, W., Athineos, D., Blyth, K., Wölfler, A., Sill, H., Zebisch, A. (2020) Loss of RAF kinase inhibitor protein is involved in myelomonocytic differentiation and aggravates RAS-driven myeloid leukemogenesis. Haematologica, 105, pp. 375-386. (doi: 10.3324/haematol.2018.209650)

Blagih, J., Zani, F., Chakravarty, P., Hennequart, M., Pilley, S., Hobor, S., Hock, A. K., Walton, J. B., Morton, J. P., Gronroos, E., Mason, S., Yang, M., Mcneish, I., Swanton, C., Blyth, K., Vousden, K. (2020) Cancer-specific loss of p53 leads to a modulation of myeloid and T cell responses. Cell Reports, 30, pp. 481-496.e6. (doi: 10.1016/j.celrep.2019.12.028)

Chalmers, A.J., Chan, C., Sebag-Montefiore, D. (2020) CTRad 10 years on: from 10-point plan to top 10 achievements. Clinical Oncology, 32, pp. 9-12. (doi: 10.1016/j.clon.2019.09.043)

Mateo, J. et al. (2020) Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncology, 21, pp. 162-174. (doi: 10.1016/S1470-2045(19)30684-9)

Ran, R., Harrison, H., Syamimi Ariffin, N., Ayub, R., Pegg, H. J., Deng, W., Mastro, A., Ottewell, P., Mason, S. M., Blyth, K., Holen, I., Shore, P. (2020) A role for CBFβ in maintaining the metastatic phenotype of breast cancer cells. Oncogene, 39, pp. 2624-2637. (doi: 10.1038/s41388-020-1170-2)

Officer, L. K., Andreou, K. E., Teodósio, A. V., He, Z., Le Quesne, J. P. (2020) Automated co-in situ hybridization and immunofluorescence using archival tumor tissue. Springer

Loveridge, C. J., Slater, S., Campbell, K. J., Nam, N. A., Knight, J., Ahmad, I., Hedley, A., Lilla, S., Repiscak, P., Patel, R., Salji, M., Fleming, J., Mitchell, L., Nixon, C., Strathdee, D., Neilson, M., Ntala, C., Bryson, S., Zanivan, S. R., Edwards, J., Robson, C. N., Goodyear, C. S., Blyth, K., Leung, H. Y. (2020) BRF1 accelerates prostate tumourigenesis and perturbs immune infiltration. Oncogene, 39, pp. 1797-1806. (doi: 10.1038/s41388-019-1106-x)

Bock, F. J., Tait, S. W.G. (2020) Mitochondria as multifaceted regulators of cell death. Nature Reviews Molecular Cell Biology, 21, pp. 85-100. (doi: 10.1038/s41580-019-0173-8)

Ghaddar, N., Wang, S., Woodvine, B., Krishnamoorthy, J., Darini, C., Van Hoef, V., Popper, H., Topisirovic, I., Larsson, O., Le Quesne, J., Koromilas, A. (2020) The integrated stress response exposes a therapeutic vulnerability in KRAS driven lung cancer. European Journal of Cancer, 138, pp. S23. (doi: 10.1016/S0959-8049(20)31126-6)

Waldron, J. A., Tack, D. C., Ritchey, L. E., Gillen, S. L., Wilczynska, A., Turro, E., Bevilacqua, P. C., Assmann, S. M., Bushell, M., Le Quesne, J. (2019) mRNA structural elements immediately upstream of the start codon dictate dependence upon eIF4A helicase activity. Genome Biology, 20, (doi: 10.1186/s13059-019-1901-2)

Clark, E., Morton, M., Sharma, S., Fisher, H., Howel, D., Walker, J., Wood, R., Hancock, H., Maier, R., Marshall, J., Bahl, A., Crabb, S., Jain, S., Pedley, I., Jones, R., Staffurth, J., Heer, R. (2019) Prostate cancer androgen receptor splice variant 7 biomarker study - a multicentre randomised feasibility trial of biomarker-guided personalised treatment in patients with advanced prostate cancer (the VARIANT trial) study protocol. BMJ Open, 9, (doi: 10.1136/bmjopen-2019-034708)

Le Quesne, J., Pritchard, C., Officer, L., Kamata, T., Smith, C., Sereno, M., Das, M., Baena, J., Al Dujaily, E. (2019) Reduced protumorigenic tumor-associated macrophages with statin use in premalignant human lung adenocarcinoma. JNCI Cancer Spectrum, 4, (doi: 10.1093/jncics/pkz101)

Wilczynska, A., Gillen, S. L., Schmidt, T., Meijer, H. A., Jukes-Jones, R., Langlais, C., Kopra, K., Lu, W.-T., Godfrey, J. D., Hawley, B. R., Hodge, K., Zanivan, S., Cain, K., Le Quesne, J., Bushell, M. (2019) eIF4A2 drives repression of translation at initiation by Ccr4-Not through purine-rich motifs in the 5’UTR. Genome Biology, 20, (doi: 10.1186/s13059-019-1857-2)

Paterson, C., Thomson, M., Caldwell, B., Young, R., McLean, A., Porteous, S., Clark, S., Messow, C. M., Kean, S., Grose, D., Lamb, C., Rizwannullah, M., James, A., Schipani, S., Wilson, C., Rulach, R., Jones, R. (2019) Radiotherapy-induced xerostomia: a randomised, double-blind, controlled trial of Visco-ease™ oral spray compared with placebo in patients with cancer of the head and neck. British Journal of Oral and Maxillofacial Surgery, 57, pp. 1119-1125. (doi: 10.1016/j.bjoms.2019.10.300)

Hoyle, A. P. et al. (2019) Abiraterone in "high-" and "low-risk" metastatic hormone-sensitive prostate cancer. European Urology, 76, pp. 719-728. (doi: 10.1016/j.eururo.2019.08.006)

Clarke, N. W. et al. (2019) Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Annals of Oncology, 30, pp. 1992-2003. (doi: 10.1093/annonc/mdz396)

Chong, M. Y., Lorimer, C. F., Mehta, S., Ibrahim, E., Brock, J., McBain, C., McLoone, P., Chalmers, A. J. (2019) An audit of the management of elderly patients with glioblastoma in the UK: have recent trial results changed treatment? CNS Oncology, 8, (doi: 10.2217/cns-2019-0017)

Liko, D., Mitchell, L., Campbell, K., Ridgway, R., Jones, C., Dudek, K., King, A., Bryson, S., Stevenson, D., Blyth, K., Strathdee, D., Morton, J. P., Bird, T., Knight, J. R.P., Willis, A. E., Sansom, O. J. (2019) Brf1 loss and not overexpression disrupts tissues homeostasis in the intestine, liver and pancreas. Cell Death and Differentiation, 26, pp. 2535-2550. (doi: 10.1038/s41418-019-0316-7)

Beckta, J. M., Bindra, R. S., Chalmers, A. J. (2019) Targeting DNA repair in gliomas. Current Opinion in Neurology, 32, pp. 878-885. (doi: 10.1097/WCO.0000000000000760)

Horwich, A. et al. (2019) EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees. Annals of Oncology, 30, pp. 1697-1727. (doi: 10.1093/annonc/mdz296)

Hasan, M. N., Rouprêt, M., Keeley, F., Cracco, C., Jones, R., Straub, M., Traxer, O., Osther, P. J. S., Brehmer, M. (2019) Consultation on UTUC, Stockholm 2018 aspects of risk stratification: long-term results and follow-up. World Journal of Urology, 37, pp. 2289-2296. (doi: 10.1007/s00345-019-02739-1)

Jung, H., Giusti, G., Fajkovic, H., Herrmann, T., Jones, R., Straub, M., Baard, J., Osther, P. J. S., Brehmer, M. (2019) Consultation on UTUC, Stockholm 2018: aspects of treatment. World Journal of Urology, 37, pp. 2279-2287. (doi: 10.1007/s00345-019-02811-w)

Birrell, F., Leung, H. Y. (2019) The Scottish prostate cryotherapy service-the role of the clinical nurse specialist. British Journal of Nursing, 28, pp. S12-S16. (doi: 10.12968/bjon.2019.28.18.S12)

Al-Mubarak, H., Vallatos, A., Gallagher, L., Birch, J., Gilmour, L., Foster, J., Chalmers, A.J., Holmes, W.M. (2019) Stacked in-plane histology for quantitative validation of non-invasive imaging biomarkers: application to an infiltrative brain tumour model. Journal of Neuroscience Methods, 326, (doi: 10.1016/j.jneumeth.2019.108372)

Venkataramani, V. et al. (2019) Glutamatergic synaptic input to glioma cells drives brain tumour progression. Nature, 573, pp. 532-538. (doi: 10.1038/s41586-019-1564-x)

Fercoq, F., Remion, E., Frohberger, S. J., Vallarino-Lhermitte, N., Hoerauf, A., Le Quesne, J., Landmann, F., Hübner, M. P., Carlin, L. M., Martin, C. (2019) IL-4 receptor dependent expansion of lung CD169+ macrophages in microfilaria-driven inflammation. PLoS Neglected Tropical Diseases, 13, (doi: 10.1371/journal.pntd.0007691)

Palma, D. A. et al. (2019) Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial. BMC Cancer, 19, (doi: 10.1186/s12885-019-5977-6)

Attard, G., Merseburger, A. S., Arlt, W., Sternberg, C. N., Feyerabend, S., Berruti, A., Joniau, S., Géczi, L., Lefresne, F., Lahaye, M., Shelby, F. N., Pissart, G., Chua, S., Jones, R. J., Tombal, B. (2019) Assessment of the safety of glucocorticoid regimens in combination with abiraterone acetate formetastatic castration-resistant prostate Cancer: a randomized, open-label phase 2 study. JAMA Oncology, 5, pp. 1159-1167. (doi: 10.1001/jamaoncol.2019.1011)

Vallatos, A., Al-Mubarak, H.F.I., Birch, J.L., Gallagher, L., Mullin, J.M., Gilmour, L., Holmes, W.M., Chalmers, A.J. (2019) Quantitative histopathologic assessment of perfusion MRI as a marker of glioblastoma cell infiltration in and beyond the peritumoral edema region. Journal of Magnetic Resonance Imaging, 50, pp. 529-540. (doi: 10.1002/jmri.26580)

Orozco, S. L., Daniels, B. P., Yatim, N., Messmer, M. N., Quarato, G., Chen-Harris, H., Cullen, S. P., Snyder, A. G., Ralli-Jain, P., Frase, S., Tait, S. W.G., Green, D. R., Albert, M. L., Oberst, A. (2019) RIPK3 activation leads to cytokine synthesis that continues after loss of cell membrane integrity. Cell Reports, 28, pp. 2275-2287.e5. (doi: 10.1016/j.celrep.2019.07.077)

Kokurewicz, K., Brunetti, E., Welsh, G.H., Wiggins, S.M., Boyd, M., Sorensen, A., Chalmers, A.J., Schettino, G., Subiel, A., DesRosiers, C., Jaroszynski, D.A. (2019) Focused very high-energy electron beams as a novel radiotherapy modality for producing high-dose volumetric elements. Scientific Reports, 9, (doi: 10.1038/s41598-019-46630-w)

Johnson, S. A., Ormsby, M. J., McIntosh, A., Tait, S. W.G., Blyth, K., Wall, D. M. (2019) Increasing the bactofection capacity of a mammalian expression vector by removal of the f1 ori. Cancer Gene Therapy, 26, pp. 183-194. (doi: 10.1038/s41417-018-0039-9)

Gomez-Roman, N., Chalmers, A. J. (2019) Patient-specific 3D-printed glioblastomas. Nature Biomedical Engineering, 3, pp. 498-499. (doi: 10.1038/s41551-019-0379-2)

Vringer, E., Tait, S. W.G. (2019) Mitochondria and inflammation: cell death heats up. Frontiers in Cell and Developmental Biology, 7, (doi: 10.3389/fcell.2019.00100)

Rudzka, D. A., Spennati, G., McGarry, D. J., Chim, Y.-H., Neilson, M., Ptak, A., Munro, J., Kalna, G., Hedley, A., Moralli, D., Green, C., Mason, S., Blyth, K., Mullin, M., Yin, H., Olson, M. F. (2019) Migration through physical constraints is enabled by MAPK-induced cell softening via actin cytoskeleton re-organization. Journal of Cell Science, 132, (doi: 10.1242/jcs.224071)

Neves, K. B., Rios, F. J., Jones, R., Evans, T. R. J., Montezano, A. C., Touyz, R. M. (2019) Microparticles from vascular endothelial growth factor pathway inhibitor-treated cancer patients mediate endothelial cell injury. Cardiovascular Research, 115, pp. 978-988. (doi: 10.1093/cvr/cvz021)

Binnewies, M., Mujal, A. M., Pollack, J. L., Combes, A. J., Hardison, E. A., Barry, K. C., Tsui, J., Ruhland, M. K., Kersten, K., Abushawish, M. A., Spasic, M., Giurintano, J. P., Chan, V., Daud, A. I., Ha, P., Ye, C. J., Roberts, E. W., Krummel, M. F. (2019) Unleashing type-2 dendritic cells to drive protective antitumor CD4+ T cell immunity. Cell, 177, pp. 556-571.e16. (doi: 10.1016/j.cell.2019.02.005)

Moore, D. A., Sereno, M., Das, M., Baena Acevedo, J. D., Sinnadurai, S., Smith, C., McSweeney, A., Su, X., Officer, L., Jones, C., Dudek, K., Guttery, D., Taniere, P., Spriggs, R. V., Le Quesne, J. (2019) In situ growth in early lung adenocarcinoma may represent precursor growth or invasive clone outgrowth—a clinically relevant distinction. Modern Pathology, 32, pp. 1095-1105. (doi: 10.1038/s41379-019-0257-1)

McAllister, M. J., Underwood, M. A., Leung, H. Y., Edwards, J. (2019) A review on the interactions between the tumour microenvironment and androgen receptor signaling in prostate cancer. Translational Research, 206, pp. 91-106. (doi: 10.1016/j.trsl.2018.11.004)

Rosenthal, R. et al. (2019) Neoantigen-directed immune escape in lung cancer evolution. Nature, 567, pp. 479-485. (doi: 10.1038/s41586-019-1032-7)

Gobin, M., Nazarov, P. V., Warta, R., Timmer, M., Reifenberger, G., Felsberg, J., Vallar, L., Chalmers, A. J., Herold-Mende, C. C., Goldbrunner, R., Niclou, S. P., Van Dyck, E. (2019) A DNA repair and cell cycle gene expression signature in primary and recurrent glioblastoma: prognostic value and clinical implications. Cancer Research, 79, pp. 1226-1238. (doi: 10.1158/0008-5472.CAN-18-2076)

Anderson, R. L., Balasas, T., Callaghan, J., Coombes, R. C., Evans, J., Hall, J. A., Kinrade, S., Jones, D., Jones, P. S., Jones, R., Marshall, J. F., Panico, M. B., Shaw, J. A., Steeg, P. S., Sullivan, M., Tong, W., Westwell, A. D., Ritchie, J. W.A. (2019) A framework for the development of effective anti-metastatic agents. Nature Reviews Clinical Oncology, 16, pp. 185-204. (doi: 10.1038/s41571-018-0134-8)

Kdadra, M., Höckner, S., Leung, H., Kremer, W., Schiffer, E. (2019) Metabolomics biomarkers of prostate cancer: A systematic review. Diagnostics, 9, (doi: 10.3390/diagnostics9010021)

Kugeratski, F. G., Atkinson, S. J., Neilson, L. J., Lilla, S., Knight, J. R.P., Serneels, J., Juin, A., Ismail, S., Bryant, D. M., Markert, E. K., Machesky, L. M., Mazzone, M., Sansom, O. J., Zanivan, S. (2019) Hypoxic cancer–associated fibroblasts increase NCBP2-AS2/HIAR to promote endothelial sprouting through enhanced VEGF signaling. Science Signaling, 12, (doi: 10.1126/scisignal.aan8247)

Caragher, S., Chalmers, A. J., Gomez-Roman, M. (2019) Glioblastoma's next top model: novel culture systems for brain cancer radiotherapy research. Cancers, 11, (doi: 10.3390/cancers11010044)

Vande Voorde, J., Ackermann, T., Pfetzer, N., Sumpton, D., Mackay, G., Kalna, G., Nixon, C., Blyth, K., Gottlieb, E., Tardito, S. (2019) Improving the metabolic fidelity of cancer models with a physiological cell culture medium. Science Advances, 5, (doi: 10.1126/sciadv.aau7314)

Hassan, S., Purdie, K. J., Wang, J., Harwood, C. A., Proby, C. M., Pourreyron, C., Mladkova, N., Nagano, A., Dhayade, S., Athineos, D., Caley, M., Mannella, V., Blyth, K., Inman, G. J., Leigh, I. M. (2019) A unique panel of patient-derived cutaneous squamous cell carcinoma cell lines provides a preclinical pathway for therapeutic testing. International Journal of Molecular Sciences, 20, (doi: 10.3390/ijms20143428)

Clyde, M., McAllister, J., Obeidallah, A., Ahmad, I. (2019) Actinomyces odontolyticus infection 3 months post-robotic-assisted laparoscopic prostatectomy. BMJ Case Reports, 12, (doi: 10.1136/bcr-2018-228184)

Lopez, J., Tait, S. W.G. (2019) Application of mito-priming to generate BCL-2 addicted cells. Humana Press

Beaumatin, F., O'Prey, J., Barthet, V. J.A., Zunino, B., Parvy, J.-P., Bachmann, A. M., O'Prey, M., Kania, E., Gonzalez, P. S., Macintosh, R., Lao, L. Y., Nixon, C., Lopez, J., Long, J. S., Tait, S. W.G., Ryan, K. N. (2019) DRAM-1 is required for mTORC1 activation by facilitating lysosomal amino acid efflux. Molecular Cell, 76, pp. 163-176.E8. (doi: 10.1016/j.molcel.2019.07.021)

Rakhit, C. P., Trigg, R. M., Le Quesne, J., Kelly, M., Shaw, J. A., Pritchard, C., Martins, L. M. (2019) Early detection of pre-malignant lesions in a KRASG12D-driven mouse lung cancer model by monitoring circulating free DNA. Disease Models and Mechanisms, 12, (doi: 10.1242/dmm.036863)

Rutherford, A., Stevenson, K., Tulk, A., Chalmers, A. J. (2019) Evaluation of four different small animal radiation plans on tumour and normal tissue dosimetry in a glioblastoma mouse model. British Journal of Radiology, 92, (doi: 10.1259/bjr.20180469)

Laskar, P., Somani, S., Altwaijry, N., Mullin, M., Bowering, D., Warzecha, M., Keating, P., Tate, R. J., Leung, H. Y., Dufès, C. (2018) Redox-sensitive, cholesterol-bearing PEGylated poly(propylene imine)-based dendrimersomes for drug and gene delivery to cancer cells. Nanoscale, 2018, pp. 22830-22847. (doi: 10.1039/c8nr08141g)

Woods, B. S. et al. (2018) Addition of docetaxel to first-line long-term hormone therapy in prostate cancer (STAMPEDE): modelling to estimate long-term survival, quality-adjusted survival, and cost-effectiveness. European Urology Oncology, 1, pp. 449-458. (doi: 10.1016/j.euo.2018.06.004)

Hussain, S. A., Birtle, A., Crabb, S., Huddart, R., Small, D., Summerhayes, M., Jones, R., Protheroe, A. (2018) From clinical trials to real-life clinical practice: the role of immunotherapy with PD-1/PD-L1 inhibitors in advanced urothelial carcinoma. European Urology Oncology, 1, pp. 486-500. (doi: 10.1016/j.euo.2018.05.011)

Tarabichi, M., Martincorena, I., Gerstung, M., Leroi, A. M., Markowetz, F., The PCAWG Evolution and Heterogeneity Working Group, , Spellman, P. T., Morris, Q. D., Lingjærde, O. C., Wedge, D. C., Van Loo, P., Yuan, K. (2018) Neutral tumor evolution? Nature Genetics, 50, pp. 1630-1633. (doi: 10.1038/s41588-018-0258-x)

Salji, M., Hendry, J., Patel, A., Ahmad, I., Nixon, C., Leung, H. Y. (2018) Peri-prostatic fat volume measurement as a predictive tool for castration resistance in advanced prostate cancer. European Urology Focus, 4, pp. 858-866. (doi: 10.1016/j.euf.2017.01.019)

Parker, C. C. et al. (2018) Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet, 392, pp. 2353-2366. (doi: 10.1016/S0140-6736(18)32486-3)

Dobbin, S. J.H., Cameron, A. C., Petrie, M. C., Jones, R. J., Touyz, R. M., Lang, N. N. (2018) Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors. Heart, 104, pp. 1995-2002. (doi: 10.1136/heartjnl-2018-313726)

Novo, D. et al. (2018) Mutant p53s generate pro-invasive niches by influencing exosome podocalyxin levels. Nature Communications, 9, (doi: 10.1038/s41467-018-07339-y)

Román-Fernández, Á., Roignot, J., Sandilands, E., Nacke, M., Mansour, M. A., McGarry, L., Shanks, E., Mostov, K. E., Bryant, D. M. (2018) The phospholipid PI(3,4)P2 is an apical identity determinant. Nature Communications, 9, (doi: 10.1038/s41467-018-07464-8)

Chauhan, D., Bartok, E., Gaidt, M. M., Bock, F. J., Herrmann, J., Seeger, J. M., Broz, P., Beckmann, R., Kashkar, H., Tait, S. W.G., Müller, R., Hornung, V. (2018) BAX/BAK induced apoptosis results in caspase-8 dependent IL-1β maturation in macrophages. Cell Reports, 25, pp. 2354-2368.e5. (doi: 10.1016/j.celrep.2018.10.087)

Amelio, I., Mancini, M., Petrova, V., Cairns, R. A., Vikhreva, P., Nicolai, S., Marini, A., Antonov, A. A., Le Quesne, J., Baena Acevedo, J. D., Dudek, K., Sozzi, G., Pastorino, U., Knight, R. A., Mak, T. W., Melino, G. (2018) p53 mutants cooperate with HIF-1 in transcriptional regulation of extracellular matrix components to promote tumor progression. Proceedings of the National Academy of Sciences of the United States of America, 115, pp. E10869-E10878. (doi: 10.1073/pnas.1808314115)

Birch, J. L., Strathdee, K., Gilmour, L., Vallatos, A., McDonald, L., Kouzeli, A., Vasan, R., Qaisi, A. H., Croft, D. R., Crighton, D., Gill, K., Gray, C. H., Konczal, J., Mezna, M., McArthur, D., Schüttelkopf, A. W., McConnell, P., Sime, M., Holmes, W. M., Bower, J., McKinnon, H. J., Drysdale, M., Olson, M. F., Chalmers, A. J. (2018) A novel small-molecule inhibitor of MRCK prevents radiation-driven invasion in glioblastoma. Cancer Research, 78, pp. 6509-6522. (doi: 10.1158/0008-5472.CAN-18-1697)

Hewit, K., Sandilands, E., Sanchez Martinez, R., James, D., Leung, H. Y., Bryant, D. M., Shanks, E., Markert, E. K. (2018) A functional genomics screen reveals a strong synergistic effect between docetaxel and the mitotic gene DLGAP5 that is mediated by the androgen receptor. Cell Death and Disease, 9, (doi: 10.1038/s41419-018-1115-7)

Bray, T. L., Salji, M., Brombin, A., Pérez-López, A. M., Rubio-Ruiz, B., Galbraith, L. C.A., Patton, E. E., Leung, H. Y., Unciti-Broceta, A. (2018) Bright insights into palladium-triggered local chemotherapy. Chemical Science, 9, pp. 7354-7361. (doi: 10.1039/c8sc02291g)

Sharma, R. A. et al. (2018) Clinical development of new drug–radiotherapy combinations. Nature Reviews Clinical Oncology, 13, pp. 627-642. (doi: 10.1038/nrclinonc.2016.79)

Fort, L., Batista, J. M., Thomason, P. A., Spence, H. J., Whitelaw, J., Tweedy, L., Greaves, J., Martin, K. J., Anderson, K. I., Brown, P., Lilla, S., Neilson, M. P., Tafelmeyer, P., Zanivan, S., Ismail, S., Bryant, D. M., Tomkinson, N. C.O., Chamberlain, L. H., Mastick, G. S., Insall, R. H., Machesky, L. M. (2018) Fam49/CYRI interacts with Rac1 and locally suppresses protrusions. Nature Cell Biology, 20, pp. 1159-1171. (doi: 10.1038/s41556-018-0198-9)

Riley, J. S., Quarato, G., Cloix, C., Lopez, J., O'Prey, J., Pearson, M., Chapman, J., Sesaki, H., Carlin, L. M., Passos, J. F., Wheeler, A. P., Oberst, A., Ryan, K. M., Tait, S. W.G. (2018) Mitochondrial inner membrane permeabilisation enables mtDNA release during apoptosis. EMBO Journal, 37, (doi: 10.15252/embj.201899238)

Carruthers, R. D., Ahmed, S. U., Ramachandran, S., Strathdee, K., Kurian, K. M., Hedley, A., Gomez-Roman, N., Kalna, G., Neilson, M. P., Gilmour, L., Stevenson, K. H., Hammond, E. M., Chalmers, A. J. (2018) Replication stress drives constitutive activation of the DNA damage response and radioresistance in glioblastoma stem-like cells. Cancer Research, 78, pp. 5060-5071. (doi: 10.1158/0008-5472.CAN-18-0569)

Lazarus, K. A., Hadi, F., Zambon, E., Bach, K., Santolla, M.-F., Watson, J. K., Correia, L. L., Das, M., Ugur, R., Pensa, S., Becker, L., Campos, L. S., Ladds, G., Liu, P., Evan, G. I., McCaughan, F. M., Le Quesne, J., Lee, J.-H., Calado, D., Khaled, W. T. (2018) BCL11A interacts with SOX2 to control the expression of epigenetic regulators in lung squamous carcinoma. Nature Communications, 9, (doi: 10.1038/s41467-018-05790-5)

Mackay, H. L., Moore, D., Hall, C., Birkbak, N. J., Jamal-Hanjani, M., Karim, S. A., Phatak, V. M., Piñon, L., Morton, J. P., Swanton, C., Le Quesne, J., Muller, P. A.J. (2018) Genomic instability in mutant p53 cancer cells upon entotic engulfment. Nature Communications, 9, (doi: 10.1038/s41467-018-05368-1)

Stehbens, S. J., Ju, R. J., Adams, M. N., Perry, S., Haass, N. K., Bryant, D. M., Pollock, P. M. (2018) FGFR2-activating mutations disrupt cell polarity to potentiate migration and invasion in endometrial cancer cell models. Journal of Cell Science, 131, (doi: 10.1242/jcs.213678)

Martinez-Zubiaurre, I., Chalmers, A. J., Hellevik, T. (2018) Radiation-induced transformation of immunoregulatory networks in the tumor stroma. Frontiers in Immunology, 9, (doi: 10.3389/fimmu.2018.01679)

Dong, L.-Q., Shi, Y., Ma, L.-J., Yang, L.-X., Wang, X.-Y., Zhang, S., Wang, Z.-C., Duan, M., Zhang, Z., Liu, L.-Z., Zheng, B.-H., Ding, Z.-B., Ke, A.-W., Gao, D.-M., Yuan, K., Zhou, J., Fan, J., Xi, R., Gao, Q. (2018) Spatial and temporal clonal evolution of intrahepatic cholangiocarcinoma. Journal of Hepatology, 69, pp. 89-98. (doi: 10.1016/j.jhep.2018.02.029)

Kruspig, B., Monteverde, T., Neidler, S., Hock, A., Kerr, E., Nixon, C., Clark, W., Hedley, A., Laing, S., Coffelt, S. B., Le Quesne, J., Dick, C., Vousden, K., Martins, C. P., Murphy, D. J. (2018) The ERBB network facilitates KRAS-driven lung tumorigenesis. Science Translational Medicine, 10, (doi: 10.1126/scitranslmed.aao2565)

Morrissey, M. A., Williamson, A. P., Steinbach, A. M., Roberts, E. W., Kern, N., Headley, M. B., Vale, R. D. (2018) Chimeric antigen receptors that trigger phagocytosis. eLife, 7, (doi: 10.7554/eLife.36688.001)

Martin, G. A., Tsim, S., Kidd, A. C., Foster, J. E., McLoone, P., Chalmers, A., Blyth, K. G. (2018) Pre-EDIT: protocol for a randomised feasibility trial of elastance-directed intrapleural catheter or talc pleurodesis (EDIT) in malignant pleural effusion. BMJ Open Respiratory Research, 5, (doi: 10.1136/bmjresp-2018-000293)

Zmuda, F., Blair, A., Liuzzi, M. C., Malviya, G., Chalmers, A. J., Lewis, D., Sutherland, A., Pimlott, S. L. (2018) An 18F-labeled poly(ADP-ribose) polymerase positron emission tomography imaging agent. Journal of Medicinal Chemistry, 61, pp. 4103-4114. (doi: 10.1021/acs.jmedchem.8b00138)

Sydes, M. R. et al. (2018) Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Annals of Oncology, 29, pp. 1235-1248. (doi: 10.1093/annonc/mdy072)

Gray, E., Butler, H. J., Board, R., Brennan, P. M., Chalmers, A. J., Dawson, T., Goodden, J., Hamilton, W., Hegarty, M. G., James, A., Jenkinson, M. D., Kernick, D., Lekka, E., Livermore, L. J., Mills, S. J., O’Neill, K., Palmer, D. S., Vaqas, B., Baker, M. J. (2018) Health economic evaluation of a serum-based blood test for brain tumour diagnosis: exploration of two clinical scenarios. BMJ Open, 8, (doi: 10.1136/bmjopen-2017-017593)

Galbraith, L., Leung, H. Y., Ahmad, I. (2018) Lipid pathway deregulation in advanced prostate cancer. Pharmacological Research, 131, pp. 177-184. (doi: 10.1016/j.phrs.2018.02.022)

Ahmad, I., Sansom, O. J. (2018) Role of Wnt signalling in advanced prostate cancer. Journal of Pathology, 245, pp. 3-5. (doi: 10.1002/path.5029)

Campbell, K. J., Tait, S. W.J. (2018) Targeting BCL-2 regulated apoptosis in cancer. Open Biology, 8, (doi: 10.1098/rsob.180002)

Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gabrilovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., Vonderheide, R. H., Pittet, M. J., Jain, R. K., Zou, W., Howcroft, T. K., Woodhouse, E. C., Weinberg, R. A., Krummel, M. F. (2018) Understanding the tumor immune microenvironment (TIME) for effective therapy. Nature Medicine, 24, pp. 541-550. (doi: 10.1038/s41591-018-0014-x)

Meiser, J., Schuster, A., Pietzke, M., Voore, J. V., Athineos, D., Oizel, K., Burgos-Barragan, G., Wit, N., Dhayade, S., Morton, J. P., Dornier, E., Sumpton, D., Mackay, G. M., Blyth, K., Patel, K. J., Niclou, S. P., Vazquez, A. (2018) Increased formate overflow is a hallmark of oxidative cancer. Nature Communications, 9, (doi: 10.1038/s41467-018-03777-w)

Arce Vargas, F. et al. (2018) Fc effector function contributes to the activity of human anti-CTLA-4 antibodies. Cancer Cell, 33, pp. 649-663.e4. (doi: 10.1016/j.ccell.2018.02.010)

Waldron, J. A., Raza, F., Le Quesne, J. (2018) eIF4A alleviates the translational repression mediated by classical secondary structures more than by G-quadruplexes. Nucleic Acids Research, 46, pp. 3075-3087. (doi: 10.1093/nar/gky108)

Patel, R., Fleming, J., Mui, E., Loveridge, C., Repiscak, P., Blomme, A., Harle, V., Salji, M., Ahmad, I., Teo, K., Hamdy, F. C., Hedley, A., van den Broek, N., Mackay, G., Edwards, J., Sansom, O. J., Leung, H. Y. (2018) Sprouty2 loss‐induced IL6 drives castration‐resistant prostate cancer through scavenger receptor B1. EMBO Molecular Medicine, 10, (doi: 10.15252/emmm.201708347)

Schmidinger, M., Danesi, R., Jones, R., McDermott, R., Pyle, L., Rini, B., Négrier, S. (2018) Individualized dosing with axitinib: rationale and practical guidance. Future Oncology, 14, pp. 861-875. (doi: 10.2217/fon-2017-0455)

Galluzzi, L. et al. (2018) Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death and Differentiation, 25, pp. 486-541. (doi: 10.1038/s41418-017-0012-4)

Holmes, W. M., Vallatos, A., Gilmour, L., Chalmers, A. J. (2018) Multiple boli arterial spin labelling for high signal-to-noise rodent brain perfusion imaging. Magnetic Resonance in Medicine, 79, pp. 1020-1030. (doi: 10.1002/mrm.26706)

Rulach, R. J., McKay, S., Neilson, S., White, L., Wallace, J., Carruthers, R., Lamb, C., Cascales, A., Marashi, H., Glen, H., Venugopal, B., Sadoyze, A., Sidek, N., Russell, J. M., Alhasso, A., Dodds, D., Laskey, J., Jones, R. J., MacLeod, N. (2018) Real world uptake, safety profile and outcomes of docetaxel in newly diagnosed metastatic prostate cancer. BJU International, 121, pp. 268-274. (doi: 10.1111/bju.14025)

Kolluri, K. K. et al. (2018) Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells. eLife, 7, (doi: 10.7554/eLife.30224)

Campbell, K. J., Dhayade, S., Ferrari, N., Sims, A. H., Johnson, E., Mason, S. M., Dickson, A., Ryan, K. M., Kalna, G., Edwards, J., Tait, S. G.W., Blyth, K. (2018) MCL-1 is a prognostic indicator and drug target in breast cancer. Cell Death and Disease, 9, (doi: 10.1038/s41419-017-0035-2)

McCarroll, C. S. et al. (2018) Runx1 deficiency protects against adverse cardiac remodeling after myocardial infarction. Circulation, 137, pp. 57-70. (doi: 10.1161/CIRCULATIONAHA.117.028911)

Bryant, D. (2018) Cell scientist to watch−David Bryant. Journal of Cell Science, 131, (doi: 10.1242/jcs.213181)

Fulton, B., Short, S. C., James, A., Nowicki, S., McBain, C., Jefferies, S., Kelly, C., Stobo, J., Morris, A., Williamson, A., Chalmers, A. (2018) PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status. Clinical and Translational Radiation Oncology, 8, pp. 12-16. (doi: 10.1016/j.ctro.2017.11.003)

Ashton, M., O'Rourke, N., Macleod, N., Laird, B., Stobo, J., Kelly, C., Alexander, L., Franks, K., Moore, K., Currie, S., Valentine, R., Chalmers, A.J. (2018) SYSTEMS-2: a randomised phase II study of radiotherapy dose escalation for pain control in malignant pleural mesothelioma. Clinical and Translational Radiation Oncology, 8, pp. 45-49. (doi: 10.1016/j.ctro.2017.11.004)

Bilsland, A., Kelly, C., Roccisana, J., Paul, J., Jones, R., Edwards, J., Roseweir, A., Stein, T., West, K. (2018) An Exploratory Study on the Use of Game-based Learning Using Microsoft Kinect to Teach Oncology Phase I Clinical Trial Designs. (doi: 10.1038/s41416-018-0299-z)

Cao, K., Tait, S. W.G. (2018) Apoptosis and cancer: force awakens, phantom menace, or both? Elsevier

Giampazolias, E., Tait, S. W.G. (2018) Caspase-independent cell death: an anti-cancer double-whammy. Cell Cycle, 17, pp. 269-270. (doi: 10.1080/15384101.2017.1408229)

Jones, R. J. (2018) Neoadjuvant vs. adjuvant chemotherapy: which is right? Springer

Thompson, M. K., Poortmans, P., Chalmers, A. J., Faivre-Finn, C., Hall, E., Huddart, R. A., Lievens, Y., Sebag-Montefiore, D., Coles, C. E. (2018) Practice-changing radiation therapy trials for the treatment of cancer: where are we 150 years after the birth of Marie Curie? British Journal of Cancer, 119, pp. 389-407. (doi: 10.1038/s41416-018-0201-z)

Altwaijry, N., Somani, S., Parkinson, J. A., Tate, R. J., Keating, P., Warzecha, M., Mackenzie, G. R., Leung, H. Y., Dufès, C. (2018) Regression of prostate tumors after intravenous administration of lactoferrin-bearing polypropylenimine dendriplexes encoding TNF-α, TRAIL, and interleukin-12. Drug Delivery, 25, pp. 679-689. (doi: 10.1080/10717544.2018.1440666)

Denton, A. E., Roberts, E. W., Fearon, D. T. (2018) Stromal cells in the tumor microenvironment. Springer

Jones, R. J. (2018) The role of medical oncologist. Springer

Dornier, E., Rabas, N., Mitchell, L., Novo, D., Dhayade, S., Marco, S., Mackay, G., Sumpton, D., Pallares, M., Nixon, C., Blyth, K., MacPherson, I. R., Rainero, E., Norman, J. C. (2017) Glutaminolysis drives membrane trafficking to promote invasiveness of breast cancer cells. Nature Communications, 8, (doi: 10.1038/s41467-017-02101-2)

Walton, J. B., Farquharson, M., Mason, S., Port, J., Kruspig, B., Dowson, S., Stevenson, D., Murphy, D., Matzuk, M., Kim, J., Coffelt, S., Blyth, K., Mcneish, I. A. (2017) CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity. Scientific Reports, 7, (doi: 10.1038/s41598-017-17119-1)

Datta, A., Sandilands, E., Mostov, K. E., Bryant, D. M. (2017) Fibroblast-derived HGF drives acinar lung cancer cell polarization through integrin-dependent RhoA-ROCK1 inhibition. Cellular Signalling, 40, pp. 91-98. (doi: 10.1016/j.cellsig.2017.09.001)

Chernova, T., Murphy, F. A., Galavotti, S., Sun, X.-M., Powley, I. R., Grosso, S., Schinwald, A., Zacarias-Cabeza, J., Dudek, K. M., Dinsdale, D., Le Quesne, J., Bennett, J., Nakas, A., Greaves, P., Poland, C. A., Donaldson, K., Bushell, M., Willis, A. E., MacFarlane, M. (2017) Long-fiber carbon nanotubes replicate asbestos-induced mesothelioma with disruption of the tumor suppressor gene Cdkn2a ( Ink4a/Arf ) Current Biology, 27, pp. 3302-3314.e6. (doi: 10.1016/j.cub.2017.09.007)

Winchester, C. L., Salji, M. J., Kasivisvanathan, V. (2017) Gathering preliminary data. Journal of Clinical Urology, 10, pp. 568-572. (doi: 10.1177/2051415817724713)

Ross, K., Jones, R. J. (2017) Immune checkpoint inhibitors in renal cell carcinoma. Clinical Science, 131, pp. 2627-2642. (doi: 10.1042/CS20160894)

MacLennan, S. et al. (2017) A core outcome set for localised prostate cancer effectiveness trials. BJU International, 120, pp. E64-E79. (doi: 10.1111/bju.13854)

Lorimer, C.F., Hanna, C., Saran, F., Chalmers, A., Brock, J. (2017) Challenges to treating older glioblastoma patients: the influence of clinical and tumour characteristics on survival outcomes. Clinical Oncology, 29, pp. 739-747. (doi: 10.1016/j.clon.2017.05.010)

Loveridge, C. J., van ’t Hof, R. J., Charlesworth, G., King, A., Tan, E. H., Rose, L., Daroszewska, A., Prior, A., Ahmad, I., Welsh, M., Mui, E. J., Ford, C., Salji, M., Sansom, O., Blyth, K., Leung, H. Y. (2017) Analysis of Nkx3.1:Cre-driven Erk5 deletion reveals a profound spinal deformity which is linked to increased osteoclast activity. Scientific Reports, 7, (doi: 10.1038/s41598-017-13346-8)

Munkley, J., Oltean, S., Vodák, D., Wilson, B. T., Livermore, K. E., Zhou, Y., Star, E., Floros, V. I., Johannessen, B., Knight, B., McCullagh, P., McGrath, J., Crundwell, M., Skotheim, R. I., Robson, C. N., Leung, H. Y., Harries, L. W., Rajan, P., Mills, I. G., Elliott, D. J. (2017) The androgen receptor controls expression of the cancer-associated sTn antigen and cell adhesion through induction of ST6GalNAc1 in prostate cancer. Oncotarget, 6, pp. 34358-34374. (doi: 10.18632/oncotarget.6024)

Gao, L., Yang, Z., Hiremath, C., Zimmerman, S. E., Long, B., Brakeman, P. R., Mostov, K. E., Bryant, D. M., Luby-Phelps, K., Marciano, D. K. (2017) Afadin orients cell division to position the tubule lumen in developing renal tubules. Development, 144, pp. 3511-3520. (doi: 10.1242/dev.148908)

Escudier, B., Faivre, S., Van Cutsem, E., Germann, N., Pouget, J.-C., Plummer, R., Vergote, I., Thistlethwaite, F., Bjarnason, G. A., Jones, R., Mackay, H., Edeline, J., Fartoux, L., Hirte, H., Oza, A. (2017) A phase II multicentre, open-label, proof-of-concept study of tasquinimod in hepatocellular, ovarian, renal cell, and gastric cancers. Targeted Oncology, 12, pp. 655-661. (doi: 10.1007/s11523-017-0525-2)

van Tuyn, J., Jaber, F., MacKenzie, D., Cole, J. J., Mann, E., Pawlikowski, J. S., Singh Rai, T., Nelson, D. M., McBryan, T., Ivanov, A., Blyth, K., Wu, H., Milling, S., Adams, P. D. (2017) Oncogene-expressing senescent melanocytes upregulate MhC class II, a candidate melanoma suppressor function. Journal of Investigative Dermatology, 137, pp. 2197-2207. (doi: 10.1016/j.jid.2017.05.030)

Crabb, S. J., Birtle, A. J., Martin, K., Downs, N., Ratcliffe, I., Maishman, T., Ellis, M., Griffiths, G., Thompson, S., Ksiazek, L., Khoo, V., Jones, R. J. (2017) ProCAID: a phase I clinical trial to combine the AKT inhibitor AZD5363 with docetaxel and prednisolone chemotherapy for metastatic castration resistant prostate cancer. Investigational New Drugs, 35, pp. 599-607. (doi: 10.1007/s10637-017-0433-4)

Ashton, M., O'Rourke, N., Currie, S., Rimner, A., Chalmers, A. (2017) The role of radical radiotherapy in the management of malignant pleural mesothelioma: a systematic review. Radiotherapy and Oncology, 125, pp. 1-12. (doi: 10.1016/j.radonc.2017.08.003)

Villa, E., Proïcs, E., Rubio-Patiño, C., Obba, S., Zunino, B., Bossowski, J. P., Rozier, R. M., Chiche, J., Mondragón, L., Riley, J. S., Marchetti, S., Verhoeyen, E., Tait, S. W.G., Ricci, J.-E. (2017) Parkin-independent mitophagy controls chemotherapeutic response in cancer cells. Cell Reports, 20, pp. 2846-2859. (doi: 10.1016/j.celrep.2017.08.087)

Bindra, R. S., Chalmers, A. J., Evans, S., Dewhirst, M. (2017) GBM radiosensitizers: dead in the water…or just the beginning? Journal of Neuro-Oncology, 134, pp. 513-521. (doi: 10.1007/s11060-017-2427-7)

Giampazolias, E. et al. (2017) Mitochondrial permeabilization engages NF-κB-dependent anti-tumour activity under caspase deficiency. Nature Cell Biology, 19, pp. 1116-1129. (doi: 10.1038/ncb3596)

Reid, S. E. et al. (2017) Tumor matrix stiffness promotes metastatic cancer cell interaction with the endothelium. EMBO Journal, 36, pp. 2373-2389. (doi: 10.15252/embj.201694912)

Riggio, A. I., Blyth, K. (2017) The enigmatic role of RUNX1 in female-related cancers - current knowledge & future perspectives. FEBS Journal, 284, pp. 2345-2362. (doi: 10.1111/febs.14059)

James, N. D. et al. (2017) Abiraterone for prostate cancer not previously treated with hormone therapy. New England Journal of Medicine, 377, pp. 338-351. (doi: 10.1056/NEJMoa1702900)

Munkley, J., McClurg, U. L., Livermore, K. E., Ehrmann, I., Knight, B., Mccullagh, P., Mcgrath, J., Crundwell, M., Harries, L. W., Leung, H. Y., Mills, I. G., Robson, C. N., Rajan, P., Elliott, D. J. (2017) The cancer-associated cell migration protein TSPAN1 is under control of androgens and its upregulation increases prostate cancer cell migration. Scientific Reports, 7, (doi: 10.1038/s41598-017-05489-5)

Bryant, D., Johnson, A. (2017) Meeting report - Intercellular interactions in context: towards a mechanistic understanding of cells in organs. Journal of Cell Science, 130, pp. 2083-2085. (doi: 10.1242/jcs.205740)

Jones, R. J., Hussain, S. A., Protheroe, A. S., Birtle, A., Chakraborti, P., Huddart, R. A., Jagdev, S., Bahl, A., Stockdale, A., Sundar, S., Crabb, S. J., Dixon-Hughes, J., Alexander, L., Morris, A., Kelly, C., Stobo, J., Paul, J., Powles, T. (2017) Randomized phase II study investigating pazopanib versus weekly paclitaxel in relapsed or progressive urothelial cancer. Journal of Clinical Oncology, 35, pp. 1770-1777. (doi: 10.1200/JCO.2016.70.7828)

Jamal-Hanjani, M. et al. (2017) Tracking the evolution of non–small-cell lung cancer. New England Journal of Medicine, 376, pp. 2109-2121. (doi: 10.1056/NEJMoa1616288)

Loveridge, C. J., Mui, E. J., Patel, R., Tan, E. H., Ahmad, I., Welsh, M., Galbraith, J., Hedley, A., Nixon, C., Blyth, K., Sansom, O., Leung, H. Y. (2017) Increased T cell infiltration elicited by Erk5 deletion in a Pten-deficient mouse model of prostate carcinogenesis. Cancer Research, 77, pp. 3158-3168. (doi: 10.1158/0008-5472.CAN-16-2565)

Gore, M. E., Jones, R. J., Ravaud, A., Kuczyk, M., Demkow, T., Bearz, A., Shapiro, J., Strauss, U. P., Porta, C. (2017) Sorafenib dose escalation in treatment-naïve patients with metastatic renal cell carcinoma: a non-randomised, open-label, Phase 2b study. BJU International, 119, pp. 846-853. (doi: 10.1111/bju.13740)

Abbosh, C. et al. (2017) Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature, 545, pp. 446-451. (doi: 10.1038/nature22364)

Hock, A. K., Cheung, E. C., Humpton, T. J., Monteverde, T., Paulus-Hock, V., Lee, P., McGhee, E., Scopelliti, A., Murphy, D. J., Strathdee, D., Blyth, K., Vousden, K. H. (2017) Development of an inducible mouse model of iRFP713 to track recombinase activity and tumour development in vivo. Scientific Reports, 7, (doi: 10.1038/s41598-017-01741-0)

Mason, M. D. et al. (2017) Adding celecoxib with or without zoledronic acid for hormone-naïve prostate cancer: long-term survival results from an adaptive, multiarm, multistage, platform, randomized controlled trial. Journal of Clinical Oncology, 35, pp. 1530-1541. (doi: 10.1200/JCO.2016.69.0677)

Rewhorn, M.J., Baxter, G., Leung, H.Y. (2017) Delayed fistula post-salvage prostate cryotherapy. Journal of Clinical Urology, 10, pp. 189-190. (doi: 10.1177/2051415814565201)

Kerr, L., Leung, H. Y., Melquiot, N., Arestis, N., Sidek, N. (2017) Lymphoma masquerading as advanced prostate cancer with lymphadenopathy. Journal of Clinical Urology, 10, pp. 174-176. (doi: 10.1177/2051415814560081)

Maddocks, O. D.K., Athineos, D., Cheung, E. C., Lee, P., Zhang, T., van den Broek, N. J.F., Mackay, G. M., Labuschagne, C. F., Gay, D., Kruiswijk, F., Blagih, J., Vincent, D. F., Campbell, K. J., Ceteci, F., Sansom, O. J., Blyth, K., Vousden, K. (2017) Modulating the therapeutic response of tumours to dietary serine and glycine starvation. Nature, 544, pp. 372-376. (doi: 10.1038/nature22056)

Arce Vargas, F. et al. (2017) Fc-optimized anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors. Immunity, 46, pp. 577-586. (doi: 10.1016/j.immuni.2017.03.013)

Karekla, E., Liao, W.-J., Sharp, B., Pugh, J., Reid, H., Le Quesne, J., Moore, D., Pritchard, C., MacFarlane, M., Pringle, J. H. (2017) Ex vivo explant cultures of non–small cell lung carcinoma enable evaluation of primary tumor responses to anticancer therapy. Cancer Research, 77, pp. 2029-2039. (doi: 10.1158/0008-5472.CAN-16-1121)

Daniels, B. P., Snyder, A. G., Olsen, T. M., Orozco, S., Oguin III, T. H., Tait, S. W.G., Martinez, J., Gale, M., Loo, Y.-M., Oberst, A. (2017) RIPK3 restricts viral pathogenesis via cell death-independent neuroinflammation. Cell, 169, pp. 301-313.e11. (doi: 10.1016/j.cell.2017.03.011)

Ichim, G., Tait, S. W.G. (2017) Cancer therapy-induced PAFR ligand expression: any role for caspase activity? Nature Reviews Cancer, 17, pp. 253. (doi: 10.1038/nrc.2017.16)

Jones, R. J., Brown, J. (2017) Circulating biomarkers in cancer care: what possible use? Practical Laboratory Medicine, 7, pp. 45-48. (doi: 10.1016/j.plabm.2016.04.004)

Holen, I., Speirs, V., Morrissey, B., Blyth, K. (2017) In vivo models in breast cancer research: progress, challenges and future directions. Disease Models and Mechanisms, 10, pp. 359-371. (doi: 10.1242/dmm.028274)

Tan, W. S., Lamb, B. W., Tan, M.-Y., Ahmad, I., Sridhar, A., Nathan, S., Hines, J., Shaw, G., Briggs, T. P., Kelly, J. D. (2017) In-depth critical analysis of complications following robot-assisted radical cystectomy with intracorporeal urinary diversion. European Urology Focus, 3, pp. 273-279. (doi: 10.1016/j.euf.2016.06.002)

Rooney, N., Riggio, A. I., Mendoza-Villanueva, D., Shore, P., Cameron, E. R., Blyth, K. (2017) Runx genes in breast cancer and the mammary lineage. Springer

Woodham, E. F., Paul, N. R., Tyrrell, B., Spence, H. J., Swaminathan, K., Scribner, M. R., Giampazolias, E., Hedley, A., Clark, W., Kage, F., Marston, D. J., Hahn, K. M., Tait, S. W.G., Larue, L., Brakebusch, C. H., Insall, R. H., Machesky, L. M. (2017) Coordination by Cdc42 of actin, contractility, and adhesion for melanoblast movement in mouse skin. Current Biology, 27, pp. 624-637. (doi: 10.1016/j.cub.2017.01.033)

Gutierrez, K. D., Davis, M. A., Daniels, B. P., Olsen, T. M., Ralli-Jain, P., Tait, S. W.G., Gale, Jr., M., Oberst, A. (2017) MLKL activation triggers NLRP3-mediated processing and release of IL-1β independently of gasdermin-D. Journal of Immunology, 198, pp. 2156-2164. (doi: 10.4049/jimmunol.1601757)

Simon, H.-U., Friis, R., Tait, S. W.G., Ryan, K. M. (2017) Retrograde signaling from autophagy modulates stress responses. Science Signaling, 10, (doi: 10.1126/scisignal.aag2791)

de Santiago, I., Liu, W., Yuan, K., O'Reilly, M., Chilamakuri, C. S. R., Ponder, B. A.J., Meyer, K. B., Markowetz, F. (2017) BaalChIP: Bayesian analysis of allele-specific transcription factor binding in cancer genomes. Genome Biology, 18, (doi: 10.1186/s13059-017-1165-7)

Hernandez-Fernaud, J. R. et al. (2017) Secreted CLIC3 drives cancer progression through its glutathione-dependent oxidoreductase activity. Nature Communications, 8, (doi: 10.1038/ncomms14206)

Wong, P. T., Roberts, E. W., Tang, S., Mukherjee, J., Cannon, J., Nip, A. J., Corbin, K., Krummel, M. F., Choi, S. K. (2017) Control of an unusual photo-claisen rearrangement in coumarin caged tamoxifen through an extended spacer. ACS Chemical Biology, 12, pp. 1001-1010. (doi: 10.1021/acschembio.6b00999)

Gomez-Roman, N., Stevenson, K., Gilmour, L., Hamilton, G., Chalmers, A. (2017) A novel 3D human glioblastoma cell culture system for modeling drug and radiation responses. Neuro-Oncology, 19, pp. 229-241. (doi: 10.1093/neuonc/now164)

Paterson, C., Allwood-Spiers, S., McCrea, I., Foster, J., McJury, M., Thomson, M., Sankaralingam, M., Grose, D., James, A., Rizwanullah, M., McLoone, P., Chalmers, A., Duffton, A. (2017) Study of diffusion weighted MRI as a predictive biomarker of response during radiotherapy for high and intermediate risk squamous cell cancer of the oropharynx: The MeRInO study. Clinical and Translational Radiation Oncology, 2, pp. 13-18. (doi: 10.1016/j.ctro.2016.12.003)

Bulusu, V., Tumanov, S., Michalopoulou, E., Van Den Broek, N., Mackay, G., Nixon, C., Dhayade, S., Schug, Z. T., Vande Voorde, J., Blyth, K., Gottlieb, E., Vazquez, A., Kamphorst, J. J. (2017) Acetate recapturing by nuclear acetyl-CoA synthetase 2 prevents loss of histone acetylation during oxygen and serum limitation. Cell Reports, 18, pp. 647-658. (doi: 10.1016/j.celrep.2016.12.055)

Ruch, T. R., Bryant, D. M., Mostov, K. E., Engel, J. N., Yap, A. (2017) Par3 integrates Tiam1 and phosphatidylinositol 3-kinase signaling to change apical membrane identity. Molecular Biology of the Cell, 28, pp. 252-260. (doi: 10.1091/mbc.E16-07-0541)

Morrissey, B., Blyth, K., Carter, P., Chelala, C., Jones, L., Holen, I., Speirs, V. (2017) The sharing experimental animal resources, coordinating holdings (SEARCH) framework: encouraging reduction, replacement, and refinement in animal research. PLoS Biology, 15, (doi: 10.1371/journal.pbio.2000719)

Correia-Melo, C., Ichim, G., Tait, S., Passos, J. F. (2017) Depletion of mitochondria in mammalian cells through enforced mitophagy. Nature Protocols, 12, pp. 183-194. (doi: 10.1038/nprot.2016.159)

Powles, T., Huddart, R. A., Elliott, T., Sarker, S.-J., Ackerman, C., Jones, R., Hussain, S., Crabb, S., Jagdev, S., Chester, J., Hilman, S., Beresford, M., Macdonald, G., Santhanam, S., Frew, J. A., Stockdale, A., Hughes, S., Berney, D., Chowdhury, S. (2017) Phase III, double-blind, randomized trial that compared maintenance lapatinib versus placebo after first-line chemotherapy in patients with human epidermal growth factor receptor 1/2-positive metastatic bladder cancer. Journal of Clinical Oncology, 35, pp. 48-55. (doi: 10.1200/JCO.2015.66.3468)

Carruthers, R., Chalmers, A. J. (2017) Improving the therapeutic ratio of radiotherapy by targeting the DNA damage response. Humana Press

Weigert, M., Binks, A., Dowson, S., Leung, E. Y.L., Athineos, D., Yu, X., Mullin, M., Walton, J. B., Orange, C., Ennis, D., Blyth, K., Tait, S. W.G., McNeish, I. A. (2017) RIPK3 promotes adenovirus type 5 activity. Cell Death and Disease, 8, (doi: 10.1038/s41419-017-0110-8)

Pécot, J., Maillet, L., Le Pen, J., Vuillier, C., Trécesson, S. d. C., Fétiveau, A., Sarosiek, K. A., Bock, F. J., Braun, F., Letai, A., Tait, S. W.G., Gautier, F., Juin, P. P. (2016) Tight sequestration of BH3 proteins by BCL-xL at subcellular membranes contributes to apoptotic resistance. Cell Reports, 17, pp. 3347-3358. (doi: 10.1016/j.celrep.2016.11.064)

Kaur, A., Denisova, O., Qiao, X., Jumppanen, M., Peuhu, E., Ahmed, S. U., Raheem, O., Haapasalo, H. K., Eriksson, J., Chalmers, A. J., Laakkonen, P. M., Westermarck, J. (2016) PP2A inhibitor PME-1 drives kinase inhibitor resistance in glioma cells. Cancer Research, 76, pp. 7001-7011. (doi: 10.1158/0008-5472.CAN-16-1134)

Marass, F., Mouliere, F., Yuan, K., Rosenfeld, N., Markowetz, F. (2016) A phylogenetic latent feature model for clonal deconvolution. Annals of Applied Statistics, 10, pp. 2377-2404. (doi: 10.1214/16-AOAS986)

Reza, M., Jones, R., Aspegren, J., Massard, C., Mattila, L., Mustonen, M., Wollmer, P., Trägårdh, E., Bondesson, E., Edenbrandt, L., Fizazi, K., Bjartell, A. (2016) Bone scan index and progression-free survival data for progressive metastatic castration-resistant prostate cancer patients who received ODM-201 in the ARADES multicentre study. European Urology Focus, 2, pp. 547-552. (doi: 10.1016/j.euf.2016.01.005)

Bryant, D. M., Yap, A. S. (2016) Editorial overview: Membrane traffic and cell polarity. Traffic, 17, pp. 1231-1232. (doi: 10.1111/tra.12433)

Lane, A., Metcalfe, C., Young, G. J., Peters, T. J., Blazeby, J., Avery, K. N.L., Dedman, D., Down, L., Mason, M. D., Neal, D. E., Hamdy, F. C., Donovan, J. L., ProtecT Study Group, (2016) Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life. BJU International, 118, pp. 869-879. (doi: 10.1111/bju.13582)

Patek, S.C., Willder, J.M., Heng, J.S., Taylor, B., Horgan, P.G., Leung, H.Y., Underwood, M.A., Edwards, J. (2016) Androgen receptor phosphorylation status at serine 578 predicts poor outcome in prostate cancer patients. Oncotarget, 8, pp. 4875-4887. (doi: 10.18632/oncotarget.13608)

Roman-Fernandez, A., Bryant, D. M. (2016) Complex polarity: building multicellular tissues through apical membrane traffic. Traffic, 17, pp. 1244-1261. (doi: 10.1111/tra.12417)

Flint, T. R., Janowitz, T., Connell, C. M., Roberts, E. W., Denton, A. E., Coll, A. P., Jodrell, D. I., Fearon, D. T. (2016) Tumor-induced IL-6 reprograms host metabolism to suppress anti-tumor immunity. Cell Metabolism, 24, pp. 672-684. (doi: 10.1016/j.cmet.2016.10.010)

Salji, M., Payne, S., Fraser, S., Lamb, C., Wallace, J., Qureshi, K., Duff, M., Hendry, D., Leung, H. Y. (2016) Basaloid carcinoma of prostate (BCP) in a patient with previous history of pelvic radiotherapy treated with total pelvic exenteration and abdominoperineal resection. Journal of Clinical Urology, 9, pp. 431-433. (doi: 10.1177/2051415814531575)

Tsim, S., Kelly, C., Alexander, L., McCormick, C., Thomson, F., Woodward, R., Foster, J. E., Stobo, D. B., Paul, J., Maskell, N. A., Chalmers, A., Blyth, K. G. (2016) Diagnostic and prognostic biomarkers in the rational assessment of mesothelioma (DIAPHRAGM) study: protocol of a prospective, multi-centre, observational study. BMJ Open, 6, (doi: 10.1136/bmjopen-2016-013324)

Lorimer, C. F., Saran, F., Chalmers, A. J., Brock, J. (2016) Glioblastoma in the elderly - how do we choose who to treat? Journal of Geriatric Oncology, 7, pp. 453-456. (doi: 10.1016/j.jgo.2016.07.005)

Salji, M., Ahmad, I., Winchester, C. (2016) Non-clinical research – laboratory based. Journal of Clinical Urology, 9, pp. 362-364. (doi: 10.1177/2051415816650134)

Harrow, S., Hanna, G.G., Faivre-Finn, C., McDonald, F., Chalmers, A. (2016) The challenges faced in developing novel drug radiation combinations in non-small cell lung cancer. Clinical Oncology, 28, pp. 720-725. (doi: 10.1016/j.clon.2016.08.004)

Meiser, J., Tumanov, S., Maddocks, O., Labuschagne, C. F., Athineos, D., Van Den Broek, N., Mackay, G. M., Gottlieb, E., Blyth, K., Vousden, K., Kamphorst, J. J., Vazquez, A. (2016) Serine one-carbon catabolism with formate overflow. Science Advances, 2, (doi: 10.1126/sciadv.1601273)

Woodward, J., Taylor, G. C., Soares, D. C., Boyle, S., Sie, D., Read, D., Chathoth, K., Vukovic, M., Tarrats, N., Jamieson, D., Campbell, K., Blyth, K., Acosta, J. C., Ylstra, B., Arends, M. J., Kranc, K. R., Jackson, A. P., Bickmore, W. A., Wood, A. J. (2016) Condensin II mutation causes T-cell lymphoma through tissue-specific genome instability. Genes and Development, 30, pp. 2173-2186. (doi: 10.1101/gad.284562.116)

Yang, Z., Zimmerman, S. E., Tsunezumi, J., Braitsch, C., Trent, C., Bryant, D. M., Cleaver, O., González-Manchón, C., Marciano, D. K. (2016) Role of CD34 family members in lumen formation in the developing kidney. Developmental Biology, 418, pp. 66-74. (doi: 10.1016/j.ydbio.2016.08.009)

Walton, J., Blagih, J., Ennis, D., Leung, E., Dowson, S., Farquharson, M., Tookman, L. A., Orange, C., Athineos, D., Mason, S., Stevenson, D., Blyth, K., Strathdee, D., Balkwill, F. R., Vousden, K. H., Lockley, M., McNeish, I. A. (2016) CRISPR/Cas9-mediated Trp53 and Brca2 knockout to generate improved murine models of ovarian high grade serous carcinoma. Cancer Research, 76, pp. 6118-6129. (doi: 10.1158/0008-5472.CAN-16-1272)

Powles, T., Sarwar, N., Stockdale, A., Sarker, S.-J., Boleti, E., Protheroe, A., Jones, R., Chowdhury, S., Peters, J., Oades, G., O’Brien, T., Sullivan, M., Aitchison, M., Beltran, L., Worth, D., Smith, K., Michel, C., Trevisan, G., Harvey-Jones, E., Wimalasingham, A., Sahdev, A., Ackerman, C., Crabb, S. (2016) Safety and efficacy of pazopanib therapy prior to planned nephrectomy in metastatic clear cell renal cancer. JAMA Oncology, 2, pp. 1303-1309. (doi: 10.1001/jamaoncol.2016.1197)

Birch, J., Clarke, C., Campbell, A. D., Campbell, K., Mitchell, L., Liko, D., Kalna, G., Strathdee, D., Sansom, O. J., Neilson, M., Blyth, K., Norman, J. C. (2016) The initiator methionine tRNA drives cell migration and invasion leading to increased metastatic potential in melanoma. Biology Open, 5, pp. 1371-1379. (doi: 10.1242/bio.019075)

Winchester, C., Salji, M. (2016) Writing a literature review. Journal of Clinical Urology, 9, pp. 308-312. (doi: 10.1177/2051415816650133)

Lamb, B. W., Tan, W. S., Eneje, P., Bruce, D., Jones, A., Ahmad, I., Sridhar, A., Baker, H., Briggs, T. P., Hines, J. E., Nathan, S., Martin, D., Stephens, R. C., Kelly, J. D. (2016) Benefits of robotic cystectomy with intracorporeal diversion for patients with low cardiorespiratory fitness: a prospective cohort study. Urologic Oncology: Seminars and Original Investigations, 34, pp. 417.e17-417.e23. (doi: 10.1016/j.urolonc.2016.04.006)

Mason, M.D. et al. (2016) Radiotherapy for prostate cancer: is it ‘what you do’ or ‘the way that you do it’? A UK perspective on technique and quality assurance. Clinical Oncology, 28, pp. e92-e100. (doi: 10.1016/j.clon.2016.05.011)

Speirs, V., Morrisey, B., Holen, I., Blyth, K., Carter, P., Chelala, C., Jones, L. (2016) SEARCHBreast: an online resource designed to increase the efficiency of using materials derived from breast cancer studies in animals. Journal of Pathology, 240, pp. 120-120. (doi: 10.1002/path.4755)

Roberts, E. W., Broz, M. L., Binnewies, M., Headley, M. B., Nelson, A. E., Wolf, D. M., Kaisho, T., Bogunovic, D., Bhardwaj, N., Krummel, M. F. (2016) Critical role for CD103 + /CD141 + dendritic cells bearing CCR7 for tumor antigen trafficking and priming of T cell immunity in melanoma. Cancer Cell, 30, pp. 324-336. (doi: 10.1016/j.ccell.2016.06.003)

Myers, S. M., Bawn, R. H., Bisset, L. C., Blackburn, T. J., Cottyn, B., Molyneux, L., Wong, A.-C., Cano, C., Clegg, W., Harrington, R. W., Leung, H., Rigoreau, L., Vidot, S., Golding, B. T., Griffin, R. J., Hammonds, T., Newell, D. R., Hardcastle, I. R. (2016) High-throughput screening and hit validation of extracellular-related kinase 5 (ERK5) inhibitors. ACS Combinatorial Science, 18, pp. 444-455. (doi: 10.1021/acscombsci.5b00155)

Ichim, G., Tait, S. W.G. (2016) A fate worse than death: apoptosis as an oncogenic process. Nature Reviews Cancer, 16, pp. 539-548. (doi: 10.1038/nrc.2016.58)

Kerr, L., Rewhorn, M. J., Longmuir, M., Fraser, S., Walsh, S., Andrew, N., Leung, H. Y. (2016) A cohort analysis of men with a family history of BRCA1/2 and Lynch mutations for prostate cancer. BMC Cancer, 16, (doi: 10.1186/s12885-016-2573-x)

Carter, P., Blyth, K., Holen, I., Jones, L., Morrissey, B., Speirs, V., Chelala, C. (2016) The SEARCHBreast portal: a virtual bioresource to facilitate the sharing of surplus animal materials derived from breast cancer studies. Open Journal of Bioresources, 3, (doi: 10.5334/ojb.21)

Ahmad, I., Mui, E., Galbraith, L., Patel, R., Tan, E. H., Salji, M., Rust, A. G., Repiscak, P., Hedley, A., Markert, E., Loveridge, C., van der Weyden, L., Edwards, J., Sansom, O. J., Adams, D. J., Leung, H. Y. (2016) Sleeping Beauty screen reveals Pparg activation in metastatic prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 113, pp. 8290-8295. (doi: 10.1073/pnas.1601571113)

Riley, J. S., Tait, S. W.G. (2016) Mechanisms of mitophagy: putting the powerhouse into the doghouse. Biological Chemistry, 397, pp. 617-635. (doi: 10.1515/hsz-2016-0137)

Morrissey, B., Holen, I., Chelala, C., Carter, P., Jones, L., Blyth, K., Speirs, V. (2016) Introducing SEARCHBreast: a virtual resource to facilitate sharing of surplus animal material developed for breast cancer research. npj Breast Cancer, 2, (doi: 10.1038/npjbcancer.2016.20)

Patella, F., Neilson, L., Athineos, D., Erami Rud Majani, Z., Anderson, K. I., Blyth, K., Ryan, K., Zanivan, S. R. (2016) In-depth proteomics identifies a role for autophagy in controlling reactive oxygen species mediated endothelial permeability. Journal of Proteome Research, 15, pp. 2187-2197. (doi: 10.1021/acs.jproteome.6b00166)

Conteduca, V., Crabb, S. J., Scarpi, E., Hanna, C., Maines, F., Joyce, H., Fabbri, P., Derosa, L., Massari, F., Lolli, C., Zarif, S., Jones, R., Caffo, O., Elliott, T., De Giorgi, U. (2016) Association between early PSA increase and clinical outcome in patients treated with enzalutamide for metastatic castration resistant prostate cancer. Molecular Diagnosis and Therapy, 20, pp. 255-263. (doi: 10.1007/s40291-016-0196-1)

Davda, R., Hughes, S., Jones, R., Crabb, S.J., Troup, J., Payne, H. (2016) Chemotherapy at first diagnosis of advanced prostate cancer – revolution or evolution? Findings from a British uro-oncology group UK survey to evaluate oncologists' views on first-line docetaxel in combination with androgen deprivation therapy in castrate-sensitive metastatic and high-risk/locally advanced prostate cancer. Clinical Oncology, 28, pp. 376-385. (doi: 10.1016/j.clon.2016.01.006)

Munkley, J., Vodak, D., Livermore, K. E., James, K., Wilson, B. T., Knight, B., Mccullagh, P., Mcgrath, J., Crundwell, M., Harries, L. W., Leung, H. Y., Robson, C. N., Mills, I. G., Rajan, P., Elliott, D. J. (2016) Glycosylation is an androgen-regulated process essential for prostate cancer cell viability. EBioMedicine, 8, pp. 103-116. (doi: 10.1016/j.ebiom.2016.04.018)

Yahyanejad, S., King, H., Iglesias, V. S., Granton, P. V., Barbeau, L. M.O., van Hoof, S. J., Groot, A. J., Habets, R., Prickaerts, J., Chalmers, A. J., Eekers, D. B.P., Theys, J., Short, S. C., Verhaegen, F., Vooijs, M. (2016) NOTCH blockade combined with radiation therapy and temozolomide prolongs survival of orthotopic glioblastoma. Oncotarget, 7, pp. 41251-41264. (doi: 10.18632/oncotarget.9275)

Morrissey, B., Blyth, K., Carter, P., Chelala, C., Jones, L., Holen, I., Speirs, V. (2016) SEARCHBreast: a new online resource to make surplus material from in vivo models of breast cancer visible and accessible to researchers. Breast Cancer Research, 18, (doi: 10.1186/s13058-016-0716-2)

Chalmers, A. J. (2016) Science in focus: combining radiotherapy with inhibitors of the DNA damage response. Clinical Oncology, 28, pp. 279-282. (doi: 10.1016/j.clon.2016.01.035)

Peck, B., Schug, Z. T., Zhang, Q., Dankworth, B., Jones, D. T., Smethurst, E., Patel, R., Mason, S., Jiang, M., Saunders, R., Howell, M., Mitter, R., Spencer-Dene, B., Stamp, G., McGarry, L., James, D., Shanks, E., Aboagye, E. O., Critchlow, S. E., Leung, H. Y., Harris, A. L., Wakelam, M. J. O., Gottlieb, E., Schulze, A. (2016) Inhibition of fatty acid desaturation is detrimental to cancer cell survival in metabolically compromised environments. Cancer and Metabolism, 4, (doi: 10.1186/s40170-016-0146-8)

Correia-Melo, C. et al. (2016) Mitochondria are required for pro-ageing features of the senescent phenotype. EMBO Journal, 35, pp. 724-742. (doi: 10.15252/embj.201592862)

Blyth, K., Carter, P., Morrissey, B., Chelala, C., Jones, L., Holen, I., Speirs, V. (2016) SEARCHBreast: a new resource to locate and share surplus archival material from breast cancer animal models to help address the 3Rs. Breast Cancer Research and Treatment, 156, pp. 447-452. (doi: 10.1007/s10549-016-3785-0)

Clarke, C. J. et al. (2016) The initiator methionine tRNA drives secretion of type II collagen from stromal fibroblasts to promote tumor growth and angiogenesis. Current Biology, 26, pp. 755-765. (doi: 10.1016/j.cub.2016.01.045)

Headley, M. B., Bins, A., Nip, A., Roberts, E. W., Looney, M. R., Gerard, A., Krummel, M. F. (2016) Visualization of immediate immune responses to pioneer metastatic cells in the lung. Nature, 531, pp. 513-517. (doi: 10.1038/nature16985)

Armstrong, A. J., Halabi, S., Eisen, T., Broderick, S., Stadler, W. M., Jones, R. J., Garcia, J. A., Vaishampayan, U. N., Picus, J., Hawkins, R. E., Hainsworth, J. D., Kollmannsberger, C. K., Logan, T. F., Puzanov, I., Pickering, L. M., Ryan, C. W., Protheroe, A., Lusk, C. M., Oberg, S., George, D. J. (2016) Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet Oncology, 17, pp. 378-388. (doi: 10.1016/S1470-2045(15)00515-X)

Gomez-Roman, N., McGregor, F., Chalmers, A. J., Plumb, J. (2016) Hypoxia-inducible factor 1 alpha is required for the tumourigenic and aggressive phenotype associated with Rab25 expression in ovarian cancer. Oncotarget, 7, (doi: 10.18632/oncotarget.7998)

Giampazolias, E., Tait, S. W.G. (2016) Mitochondria and the hallmarks of cancer. FEBS Journal, 283, pp. 803-814. (doi: 10.1111/febs.13603)

Lopez, J., Bessou, M., Riley, J. S., Giampazolias, E., Todt, F., Rochegüe, T., Oberst, A., Green, D. R., Edlich, F., Ichim, G., Tait, S. W.G. (2016) Mito-priming as a method of engineered Bcl-2 addiction. Nature Communications, 7, (doi: 10.1038/ncomms10538)

Marusiak, A. A., Stephenson, N. L., Baik, H., Trotter, E. W., Li, Y., Blyth, K., Mason, S., Chapman, P., Puto, L. A., Read, J. A., Brassington, C., Pollard, H. K., Phillips, C., Green, I., Overman, R., Collier, M., Testoni, E., Miller, C.J., Hunter, T., Sansom, O.J., Brognard, J. (2016) Recurrent MLK4 loss-of-function mutations suppress JNK signaling to promote colon tumorigenesis. Cancer Research, 76, pp. 724-735. (doi: 10.1158/0008-5472.can-15-0701-t)

Cheung, E., Lee, P., Ceteci, F., Nixon, C., Blyth, K., Sansom, O., Vousden, K. (2016) Opposing effects of TIGAR- and RAC1-derived ROS on Wnt-driven proliferation in the mouse intestine. Genes and Development, 30, pp. 52-63. (doi: 10.1101/gad.271130.115)

Niyazi, M., Brada, M., Chalmers, A. J., Combs, S. E., Erridge, S. C., Fiorentino, A., Grosu, A. L., Lagerwaard, F. J., Minniti, G., Mirimanoff, R.-O., Ricardi, U., Short, S. C., Weber, D. C., Belka, C. (2016) ESTRO-ACROP guideline 'target delineation of glioblastomas' Radiotherapy and Oncology, 118, pp. 35-42. (doi: 10.1016/j.radonc.2015.12.003)

Wagstaff, J., Jones, R., Hawkins, R., Porfiri, E., Pickering, L., Bahl, A., Brown, J., Buchan, S. (2016) Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry. Annals of Oncology, 27, pp. 159-165. (doi: 10.1093/annonc/mdv504)

Powles, T., Brown, J., Larkin, J., Jones, R., Ralph, C., Hawkins, R., Chowdhury, S., Boleti, E., Bhal, A., Fife, K., Webb, A., Crabb, S., Geldart, T., Hill, R., Dunlop, J., Hall, P. E., McLaren, D., Ackerman, C., Beltran, L., Nathan, P. (2016) A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK) Annals of Oncology, 27, pp. 880-886. (doi: 10.1093/annonc/mdw014)

James, N. D. et al. (2016) Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform-randomised controlled trial. Lancet, 387, pp. 1163-1177. (doi: 10.1016/S0140-6736(15)01037-5)

Fulton, B., Jones, R. J. (2016) Combination treatment strategies with docetaxel in patients with metastatic prostate. Springer

Klionsky, D. J. et al. (2016) Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) Autophagy, 12, pp. 1-222. (doi: 10.1080/15548627.2015.1100356)

Oberst, A., Ichim, G., Tait, S. W.G. (2016) Mitochondrial permeabilization: from lethality to vitality. Springer

Roseweir, A. K., Qayyum, T., Lim, Z., Hammond, R., MacDonald, A. I., Fraser, S., Oades, G. M., Aitchison, M., Jones, R. J., Edwards, J. (2016) Nuclear expression of Lyn, a Src family kinase member, is associated with poor prognosis in renal cancer patients. BMC Cancer, 16, pp. 229. (doi: 10.1186/s12885-016-2254-9)

Conteduca, V., Crabb, S. J., Jones, R. J., Caffo, O., Elliott, T., Scarpi, E., Fabbri, P., Derosa, L., Massari, F., Numico, G., Zarif, S., Hanna, C., Maines, F., Joyce, H., Lolli, C., De Giorgi, U. (2016) Persistent neutrophil to lymphocyte ratio >3 during treatment with enzalutamide and clinical outcome in patients with castration-resistant prostate cancer. PLoS ONE, 11, (doi: 10.1371/journal.pone.0158952)

Roberts, E.W., Denton, A.E., Fearon, D.T. (2016) Roles of stromal cells in the immune system. Elsevier